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Abstract 
 
In this work, a series of inhibitors of two enzymes, aspartate transcarbamoylase 
(ATCase) and fructose 1,6-bisphosphatase (FBPase) were designed, synthesized and 
characterized.  ATCase catalyzes the committed step in pyrimidine nucleotide 
biosynthesis, the reaction between carbamoyl phosphate (CP) and L-aspartate to form N-
carbamoyl-L-aspartate (CA) and inorganic phosphate. This step is exceptionally 
important because once CA is formed, it is committed to the biosynthesis of pyrimidines, 
a necessary component for nucleic acid biosynthesis. The pyrimidine biosynthetic 
pathway plays an important regulatory role in cell proliferation since there is evidence 
that intracellular nucleotide pools control DNA replication and consequently cell 
division. Thus, the enzymes of pyrimidine biosynthesis, both in the de novo and salvage 
pathways, are targets for anti-proliferation drugs.  Fructose 1,6-bisphosphatase (FBPase) 
is responsible for the hydrolysis of fructose 1,6-bisphosphate (F16BP) to fructose 6-
phosphate (F6P).  As the key enzyme at the control point in the gluconeogenesis 
  
pathway, FBPase presents an opportunity for the development of novel inhibitors against 
type-2 diabetes aimed at lowering the hepatic glucose production in type-2 diabetes.  
With ATCase, the design, synthesis and characterization of (1) T-state inhibitors 
composed of two phosphonacetamide groups linked together by a variety of 
functionalities and (2) analogs of N-phosphonacetyl-L-aspartate, a potent inhibitor of 
ATCase, were accomplished.  With FBPase, a library of allosteric inhibitors, of which, 
the lead compound was initially identified through a virtual high-throughput screening 
system, was developed.  In addition, this work also aimed to find the in vivo target for 
achyrofuran, a natural product derived from Achyrocline satureoides which has been 
shown to significantly lower blood glucose levels in db/db mouse for type-2 diabetes.  
The last project presented evidences that FBPase is the likely in vivo target for 
achyrofuran.  This was accomplished through the use of computational docking 
experiments and by the synthesis of a new class of inhibitors based on the achyrofuran 
scaffold. 
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Introduction 
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1.1  Enzymes as Drug Targets 
 
Many drugs produce their pharmacologic effects by inhibiting enzymes. In fact, 
the global revenues for enzyme inhibitors were more than $32.1 billion in 2005.  At an 
average annual growth rate of 5.1%, this market is estimated to surpass $43 billion by 
2011.1 In light of the above data, it is not surprising that much of the drug discovery and 
development efforts at present are focused on identifying and optimizing drug candidates 
that act through inhibition of specific enzyme targets.  
 
Rationales for Choosing Enzymes as Drug Targets 
There are several rationales for choosing to focus on enzymes as drug targets.  
One of the main attractions for targeting enzymes stems from the high levels of disease 
association that are characterized by this class of proteins.  For example, chemical 
deficiencies can be corrected by inhibiting the enzyme that uses the chemical of interest 
as a substrate.  Specifically, low levels of the inhibitory neurotransmitter γ-aminobutyric 
acid (GABA) in the brain, can lead to convulsions as well as other neurological disorders 
such as Alzheimer’s disease1 and Huntington’s chorea.2 It is well established that γ-
aminobutyric acid aminotransferase (GABA-AT, E.C. 2.6.1.19) is the enzyme that is 
responsible for degrading GABA and therefore, inhibition of GABA-AT results in the 
higher concentration of GABA in the brain, producing an anticonvulsant effect.3   
 
                                                
1 www.marketresearch.com, “Enzyme Inhibitors with broad therapeutic applications”, 1 June, 
2006. 
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Conversely, chemical excess can be corrected by inhibiting the enzyme 
responsible for producing the molecule.  An example where the excess of a particular 
metabolite results in a disease state, is with the excess of uric acid, which can lead to 
gout. Xanthine oxidase (XO, EC 1.17.3.2) is the enzyme responsible for converting 
xanthine to uric acid.4 Therefore, the inhibition of XO decreases the uric acid levels, and 
produces an antihyperuricemic effect.  Allopurinol5 is a well-known XO inhibitor that is 
clinically used in the therapy of gout.   
 
A third example can be found in certain infectious diseases, where specific 
enzymes of the invading organism that are critical for its survival or replication, can be 
targeted by drug therapy.  For instance, the enzymes 6-hydroxymethylpterin 
pyrophosphokinase (HPPK, EC 2.7.6.3) and dihydropteroate synthase (DHPS, EC 
2.5.1.15) catalyze sequential steps in folate biosynthesis. These enzymes are present in 
microorganisms but absent in mammals and therefore are especially suitable targets for 
antimicrobials.6 Sulfa drugs (sulfonamides and sulfones) are commonly used as 
antimicrobials targeting DHPS7 and they act by competing with para-aminobenzoic acid 
for incorporation of folic acid.  
 
Therefore, given the rationales that have been put forth, it should not come as a 
surprise that within every major therapeutic area that is targeted by the pharmaceutical 
industry, one can find numerous examples of enzyme inhibitors in clinical use.8   
 
   4 
1.2  Overview of the Pyrimidine Nucleotide Biosynthetic Pathway 
 
Pyrimidine nucleotide biosynthesis in all organisms proceeds according to the 
general scheme shown in Figure 1.9,10 The first reaction of pyrimidine biosynthesis is the 
synthesis of carbamoyl phosphate (CP) from bicarbonate and glutamine or ammonia.  
This reaction is catalyzed by the cytosolic enzyme carbamoyl phosphate synthetase II 
(CPSase EC 6.3.5.5).  Unlike purine bases, the pyrimidine orotate (Figure 1) is 
synthesized without ribose-5-phosphate in three steps starting from carbamoyl phosphate 
and aspartate.  The condensation of CP and aspartate (Asp)11 to form carbamoyl aspartate 
(CA) is catalyzed by aspartate transcarbamoylase (ATCase EC 2.1.3.2).  The third 
reaction is the intramolecular condensation catalyzed by dihyroorotase (DHOase EC 
3.5.2.3) to yield dihydroorotate.  Dihydroorotate is then irreversibly oxidized to orotate 
by dihydroorotate dehydrogenase (EC 1.3.31).  Orotate then reacts with 5-phosphoribosyl 
1-pyrophosphate (PRPP) to yield orotidine-5’-monophosphate (OMP) in a reaction 
catalyzed by orotate phosphoribosyl transferase (EC 2.4.2.10).  This reaction is driven by 
the hydrolysis of the inorganic phosphate and fixes the anomeric form of pyrimidine 
nucleotides in the β configuration.  Orotate phosphoribosyl transferase also salvages 
other pyrimidine bases, such as uracil and cytosine, by converting them to their 
corresponding nucleotides.  The final reaction of the pathway is the decarboxylation of 
OMP by OMP decarboxylase (EC 4.1.1.23) to form uridine monophosphate (UMP).   
 
   5 
In bacteria, a separate enzyme catalyzes each of the steps.  In Neurospora and 
yeast, CPSase activity dedicated to pyrimidine biosynthesis resides on the same 
polypeptide as the ATCase activity12 while the remaining enzymes are separate.  
Pyrimidine biosynthesis in mammalian cells involves two multifunctional proteins: the 
CPSase/ATCase/DHOase (CAD) complex, a 210 KD polypeptide chain and the 
OPRTase/ODCase complex.10 An enzyme of the inner mitochondrial membrane carries 
out the intervening step, dehydrogenation of dihydroorotate.10,13 
 
Finally, the synthesis of uridine triphosphate (UTP) from UMP occurs by the 
sequential actions of a nucleoside monophosphate kinase14 and nucleoside diphosphate 
kinase.15 Cytidine triphosphae (CTP) is formed by amination of UTP by CTP synthetase.  
In mammals, the amino group is donated by glutamine,16 whereas in bacteria, it is 
supplied by ammonia.17,18 
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Figure 1.1.  Pyrimidine nucleotide biosynthetic pathway. 
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1.3 Structure and Function of Escherichia coli (E.coli) ATCase 
 
Function of ATCase 
Aspartate transcarbamoylase in E.coli, catalyzes the committed step in the de 
novo pyrimidine biosynthesis pathway, where the condensation of carbamyl phosphate 
(CP) and L-aspartate (Asp) occurs to produce N-carbamoyl-L-aspartate (CA) and 
inorganic phosphate (Pi).19 ATCase catalyzes the reaction in an ordered-binding manner 
i.e. with CP binding before Asp and similarly, with CA leaving the active site before Pi.20 
This reaction is exceptionally important because once CA is form, it is committed to the 
biosynthesis of pyrimidines (Figure 1.1), a necessary component for nucleic acid 
biosynthesis.  
 
Allosteric Nature of ATCase 
ATCase belongs to a special class of allosteric enzymes that can make significant 
changes in their catalytic ability over a narrow range of substrate concentrations.11 The 
enzyme exhibits homotropic cooperativity for one of its substrate, Asp21 and the result of 
which is a sigmoidal substrate saturation curve.  This phenomenon often occurs as soon 
as the first molecule binds and induces changes in the substrate and/or catalytic activity 
of other, sometimes distant binding sites.  The allowed conformational states of allosteric 
enzymes can be understood by looking either at the Modnod, Wyman and Changeux22 or 
the Koshland, Nemethy and Filmer23 models.  Though both models have different 
assumptions about the exact behavior that occurs upon substrate binding, both are in 
   8 
agreement that the subunits of the enzymes must exist in one of two states, often called 
the T and R states.  The two states differ in substrate affinity and activity, with the T state 
having lower activity and lower affinity for substrate than the R state. 
 
With ATCase, it has been determined that the R state can be induced by the 
binding of substrates as well as substrate analogs such as N-phosphonacetyl-L-aspartate 
(PALA, see section 1.4).  Besides PALA, the enzyme can also be converted from the T to 
the R state through the binding of CP and succinate, an analog of Asp.  More importantly, 
this conversion has been well studied and has been observed in several experiments such 
as circular dichroism,24,25 small angle x-ray scattering,26,27 difference sedimentation28 and 
ultraviolet difference spectroscopy29 and X-ray crystallography.30 During the T to R 
transition, the enzyme increases approximately 11 Å along the molecular threefold axis31 
(Figure 1.4). 
 
In addition, the activity of the enzyme is influenced heterotropically by CTP, UTP 
and adenosine triphosphate (ATP).32 This is because the enzyme controls the rate of 
pyrimidine biosynthesis by altering its catalytic activity in response to cellular levels of 
both pyrimidines and purines.  Both CTP and UTP, the end products of pyrimidine 
biosynthesis cause a decrease in velocity through feedback inhibition of the enzyme 
(Figure 1.2) while ATP; an end product of the parallel purine biosynthesis pathway 
causes an increase in velocity.  In part, the relative amounts of purines and pyrimidines in 
the cell are thereby kept in balance for nucleic acid synthesis.   
   9 
Quaternary Structure 
The E.coli ATCase holoenzyme (Mr 330 000) is composed of twelve polypeptide 
chains, which is made up of two catalytic subunits, (C3, Mr 100 000) each made up of 
three identical chains, and three regulatory subunits (R2, Mr 34 000), each comprised of 
two identical polypeptide chains.  The C3 and R2 subunits can be isolated apart from each 
other by dissociating the holoenzyme.33 In doing so, the specific activity of C3 was 
determined to be approximately 50% higher than that of the holoenzyme.11    
 
Binding Sites 
The active sites are located in the catalytic subunits while each regulatory chain 
has a single binding site for all regulatory effectors. Both CTP and ATP bind to the same 
site on the regulatory chain.  The nucleotide-binding sites on the holoenzyme, are located 
approximately 60 Å from the closest active site.  In addition to the nucleotide-binding 
sites, each regulatory chain also contains the zinc domain (Figure 1.3), which contains a 
structural zinc atom coordinated tetrahedrally to four cysteine residues.  Each catalytic 
chain possesses two structural domains – the aspartate domain that contains most of the 
binding loci for the substrate Asp and the carbamoyl phosphate domain that contains 
most of the binding loci for the substrate CP.34  
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Figure 1.2. The reaction carried out by ATCase and the feedback inhibition by CTP. 
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Figure 1.3. The structural overview of one catalytic (green) and one regulatory (blue) 
chain of ATCase in the T state of E.coli ATCase with CTP and Zn (red) bound. (PDB 
code 1za1).35 The Zn atom is coordinated tetrahedrally to four cysteine residues from the 
regulatory chain.   
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Figure 1.4. Allosteric transition from the low affinity, low activity T state to the high 
affinity, high activity R state.  During the allosteric transition, the enzyme undergoes an 
11Å transition along its vertical axis. 
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1.4 Inhibitors Against ATCase 
 
The pyrimidine biosynthetic pathway plays an important regulatory role in cell 
proliferation since there is evidence that intracellular nucleotide pools control DNA 
replication and consequently cell division.9,36 As such, the enzymes of pyrimidine 
biosynthesis, both in the de novo and salvage pathways, have become targets for anti-
proliferation drugs.   
 
Bi-substrate analog: N-(phosphonacetyl)-L-aspartate (PALA) 
Among them, PALA was found to be a potent inhibitor of ATCase.  PALA is a 
bi-substrate analog of ATCase and it combines, in one molecule, most of the structural 
features of the two natural substrates, CP and Asp (Figure 1.5).37 The inhibition of PALA 
is competitive with respect to CP and noncompetitive with respect to Asp.  PALA was 
found to bind tightly to ATCases of bacterial37 (E.coli, Ki = 27 nM), murine38 (spleen 
cells, Ki = 26 nM) and human39 (spleen cells, Ki = 11 nM) origin.      
 
Since its synthesis more than 25 years ago, PALA has been in clinical trials and 
its mechanism of action has been well characterized.  In vivo, low doses of PALA inhibit 
whole body pyrimidine synthesis.  While this action is cytotoxic in vitro, extensive 
human testing demonstrates that PALA alone is devoid of selective antitumor activity.40 
Therefore, most interest in the therapeutic action of PALA derives from its use in 
combination with other antitumor drugs such as methotrexate, 5-fluorouracil (5FU), L-
   14 
alanosine, thymidine and 6-methylmercaptopurine. The reason for this can be illustrated 
in its use in combination with 5FU. 5FU is converted to fluorouracil triphosphate 
(FUTP), which is then incorporated into cellular RNA, leading to impairments in RNA 
processing, ultimately resulting in cell death.  The conversion of 5FU to FUTP requires 
phosphoribosyl-pyrophosphate as the co-factor. It has been suggested that the natural 
nucleoside uridine and its corresponding phosphates may compete with 5FU for the target 
enzyme, thus reducing its efficacy. As such, PALA is typically administered prior to 5FU 
to induce depletion in the nucleoside pools, resulting in an increase in FUTP 
concentrations, thus favoring the incorporation of FUTP into RNA.41 As mentioned 
above, despite all its promise as an anticancer agent, PALA, when used alone, has failed 
to inhibit pyrimidine biosynthesis in vivo as strongly as expected from its efficacy in 
vitro. This is despite an apparent effective concentration of the drug detected in tissues.42 
This has been widely attributed to the difficulty in transporting PALA to its sites of 
action.43 Thus, a significant amount of research has also been done to develop alternative 
forms of PALA, with the objective of easing of delivery.  Most notably, are works in the 
areas of developing the pro-drug form44 that can be activated upon intake and of the 
encapsulation of PALA in liposomes.45-47 
 
Structure-Based Inhibitors Inspired by PALA 
The success of PALA as a specific inhibitor of ATCase has prompted several 
groups to focus their research efforts on improving the affinity of PALA for ATCase.  
Kafarski et al48 synthesized a series of N-(phosphonoacetyl)amino phosphonates which 
   15 
were classified as phosphonate analogs of PALA.  However, replacing the carboxyl 
moieties in PALA by a phosphonic function resulted in a total abolition of antitumor 
activity.  When the aspartate moiety on PALA is substituted by glutamate, Grison et al49, 
found that the inhibitor (2. PALG) failed to inhibit E.coli ATCase at concentrations 
lower than 1 mM.   Grison et al also synthesized analogs of PALA where hydrogens in 
the α-position relative to the phosphorus atom were replaced by one (3. PALA(F)) or 
two fluorine atoms (4. PALA(FF)).  Unfortunately, 3 only inhibited the enzyme to 45% 
at 5 mM while 4 failed to exert any inhibitory activity against E.coli ATCase.  In 2006, 
Eldo et al.50 reported the synthesis of N-phosphonacetyl-L-isoasparagine (5. PALI) in 
which the α-carboxyl on the aspartate portion of PALA was substituted by an amide.  
Through a fluorescence binding experiment, 5 was determined to have a Kd of 2.0 µM 
relative to 0.69 µM for PALA in the same experiment.  The crystal structure of the 
ATCase•5 complex showed 22 hydrogen-bonding interactions between the enzyme and 
5.  All residues that interact with PALA were observed to interact with 5 and overall, the 
binding of 5 is very similar to that of PALA.    
 
Other ATCase Inhibitors  
Inhibitors that are dissimilar to PALA had also been synthesized and 
characterized.  Balbaa et al.51 had synthesized a series of phenobarbital derivatives as 
inhibitors of ATCase.  These derivatives were designed to be structurally related to 
pyrimidines as ATCase from rat liver was found to be inhibited by thymidine.52 
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Compounds 6 and 7 inhibited purified rat liver ATCase at 117 µM and 76 µM 
respectively.   
   17 
 
 
 
 
Figure 1.5. The schematic diagram of ATCase with PALA bound at the active site in the 
catalytic chain (PDB code: 1D09).53 The hydrogen bonding interactions between the 
enzyme and PALA are shown as dotted lines. The figure was created using Ligplot.54 
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Figure 1.6. Inhibitors against ATCase. 
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1.5 Overview of the Gluconeogenesis Pathway 
 
Glucose can be synthesized from non-carbohydrate precursors, such as pyruvate 
and lactic acid, via the gluconeogenesis pathway.  Gluconeogenesis is a predominantly 
hepatic pathway by which three-carbon precursors are converted enzymatically to 
glucose. The majority of the enzymes of gluconeogenesis also catalyze the reverse 
reactions involved in glycolysis, but there are four unidirectional enzymes which together 
with their glycolytic counterparts form the so-called substrate cycles of the pathway: 
pyruvate carboxylase (PC, EC 6.4.1.1) and phosphoenolpyruvate carboxykinase (PEPCK, 
EC 4.1.1.32) (lower cycle), fructose-1,6-bisphosphatase (FBPase, EC 3.1.3.11) (middle 
cycle), and glucose-6-phosphatase (G6Pase, EC 3.1.3.9) (upper cycle). Other than the 
interconversion of F6P and F16BP, the conversion between glucose and G6P, PEP and 
pyruvate are also catalyzed by different enzymes in both forward and reverse directions 
and are therefore potential points for regulating glycolytic versus gluconeogenesis flux.55 
 
Gluconeogenesis begins with the conversion of pyruvate to phosphoenolpyruvate 
(PEP) via the formation of oxaloacetate, a reactive intermediate.  The exergonic 
decarboxylation of oxaloacetate provides the free energy necessary for the formation of 
PEP and this reaction is catalyzed by PC and PEPCK.  
 
 The route from PEP to fructose-1,6-bisphosphate (F16BP) is catalyzed by the 
enzymes of glycolysis operating in reverse.  In the middle cycle, F16BP is subsequently 
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hydrolyzed by FBPase to give fructose-6-phosphate (F6P).  F6P is then isomerized to 
glucose-6-phosphate (G6P), which is then hydrolyzed by glucose-6-phosphatase 
(G6Pase). Both FBPase and G6Pase are endogenous to the gluconeogenesis pathway.  
G6Pase is found only in the liver and kidney.  Overall, the net energetic cost of 
converting two pyruvate molecules to one glucose molecule by gluconeogenesis is six 
ATP equivalents. 
 
Regulation of Gluconeogenesis 
Gluconeogenesis and its reciprocal pathway, glycolysis, do not proceed 
simultaneously in vivo, but are reciprocally regulated to meet the needs of the organism.  
For example, F26BP is a natural inhibitor of FBPase while acting as an activator of 
phosphofructokinase.  When glucose concentrations are low, cAMP levels subsequently 
increase due to glucagon secretion in liver cells.  The resultant increase in cAMP 
concentrations activates the protein kinase, cAPK to phosphorylate and activate FBPase-
2, which leads to the inactivation of PFK-2.  The net decrease in F26BP levels hence 
favors the synthesis of F16BP and results in an increase in gluconeogenesis.  
 
The activity of gluconeogenesis can also be regulated at two other substrate cycles 
in glucose metabolism (Figure 1.8).  Other than the interconversion of F6P and F16BP, 
the conversion between glucose and G6P, PEP and pyruvate, being catalyzed by different 
enzymes in both forward and reverse directions, are therefore potential points for 
regulating glycolytic versus gluconeogenesis flux. 
   21 
   
 
 
Glucose
Glucose-6-phosphatase
Fructose-6-phosphate
O
HO
HO
OH
OH
OH
O
HO
HO
H
OH
OH
OPO3
2-
Glucose-6-phosphate
Fructose-1,6-bisphosphate
Dihyroxyacetone
phosphate
Glyceraldehyde-3-phosphate
Glycerol Pyruvate
Fructose-1,6,bisphosphatase
Phosphoglucose
isomerase
OH
O
O
P
OH
OHHO
O
O
P
OH
O
OH
OH
OH
O
O
P
OH
OHHO
O
OH
OH
 
 
Figure 1.7. Gluconeogenesis pathway beginning from pyruvate and glycerol.  
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Figure 1.8. Substrate cycles in glucose metabolism.  The interconversions of glucose and 
G6P, F6P and FBP, and PEP and pyruvate are catalyzed by different enzymes in the 
forward and reverse directions. (Figure was reproduced from Voet, D, Voet, J. G., Pratt, 
C, W. Fundamentals of Biochemistry) 
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1.6 Structure and Function of FBPase 
 
Function of FBase 
 Fructose 1,6-bisphosphatase (FBPase, EC 3.1.3.11) is a key regulatory enzyme in 
the gluconeogenesis pathway and catalyzes the hydrolysis of fructose 1,6-bisphosphate 
(F16BP) to fructose 6-phosphate (F6P) and inorganic phosphate (Pi)56 in the presence of 
divalent ions, namely Mg2+, Mn2+ or Zn2+.57,58  
 
Homology between FBPases of Different Origins 
 FBPases from pig kidney, rat liver, human liver and sheep liver have all been 
purified and studied.  Their complete amino acid sequence have been analyzed and the 
primary sequence found to have 85% or greater homology with respect to one another.59   
In E.coli, the amino acid sequence is 45% identical and 55% similar to that of pig kidney.  
Similar homology also extends to FBPase from plants and yeast suggesting that FBPase 
has undergone minimal changes throughout evolution, even though regulation of the 
enzyme differs in different cell types.60   
 
Quaternary Structure  
The most detailed structural data are for the pig kidney enzyme61 although the 
mammalian enzymes, in general, are thought to exist as a homotetramer and have an 
average Mr of 37,000 per subunit.  For the pig kidney enzyme, the tertiary structure of 
each subunit is divided into two folding domains, the adenosine monophosphate (AMP) 
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and the F16BP domains.  The AMP binding site of each subunit is approximately 30 Å 
away from the active site.  The metal-binding sites are located between the F16BP and 
AMP domains.62 (Figure 1.9) 
 
Binding Sites 
The enzyme is competitively inhibited by fructose 2,6-bisphophatase (F26BP), 
which binds to the substrate-binding site and it is allosterically inhibited by AMP, which 
binds cooperatively to the allosteric sites.63 The binding of F26BP and AMP inhibit 
FBPase while simultaneously activating its counterpart in glycolysis, 6-phosphofructose 
kinase (EC 2.7.1.11).       
  
 FBPase has three metal binding sites (sites 1, 2 and 3) in each subunit.64,65 It was 
proposed that FBPase has an ordered loop (residues 52-72) in the active R-state with 
three metals bound. AMP alone displaces loop 52-72 from its engaged conformation and 
abolishes metal association with sites 2 and 3.62   
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Figure 1.9. Structures of Adenosine monophosphate (8. AMP) and fructose-2,6 
bisphosphate (9. F26BP) 
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Allosteric Regulation 
 The regulatory properties of FBPase have been extensively studied.  It has been 
found that the enzyme activity is regulated in vivo by the substrate analog F26BP and by 
AMP, which binds to the active site and allosteric site respectively.  
 
As an allosteric enzyme, FBPase exists in at least two distinct quaternary 
conformations known as the T and R state respectively.  Unlike ATCase, kinetic data 
have shown that FBPase is normally in the active R state.  The binding of substrates or 
products, in combination with metal cations help stabilizes the R-state conformation.  
When AMP binds, it then induces the conformational transition from the high activity R-
state to the less active (or inactive) T-state.  During the R to T transition, the upper dimer 
rotates approximately 17° relative to the bottom dimer, producing the T state 
conformation.62,66 
 
A proposed mechanism for the allosteric regulation of catalysis involves three 
conformational states of loop 52-72 called engaged, disengaged and disordered.  In the 
active forms of the enzyme, loop 52-72 probably cycles between its engaged and 
disengaged conformations.  AMP alone or with F26BP stabilizes a disengaged loop, 
whereas metal cations with products stabilize the engaged loop.67 It has also been 
proposed that during the allosteric transition, the F16P domain would interact with 
neighboring domains while maintaining its internal structure.  On the other hand, within 
each AMP domain, there are notable changes with respect to its internal structure as well 
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as in its interactions with neighboring AMP units.   These changes within the AMP 
domains were thought to result from small initial changes propagating to other parts of 
the molecule by the concerted movement of neighboring AMP domains.68   
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Figure 1.10. Schematic representation61 of the quaternary structure of fructose-1,6 
bisphosphatase viewed down a molecular twofold axis.  Each of the subunits is composed 
of two folding domains.  The AMP binding site (X) can be found within the AMP 
domain while the active site is found within the fructose-1,6 bisphophatase (Fbp) domain.  
The divalent metal ions are located between the AMP and Fbp domains ().69 
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1.7  Inhibitors of FBPase 
 
Fructose 1,6-bisphosphatase is a key control point in the gluconeogenesis 
pathway and is responsible for the hydrolysis of F16BP to F6P, and thus presents an 
opportunity for the development of novel therapeutics.  The main focus of developing 
inhibitors against FBPase is aimed at lowering the hepatic glucose production in type 2 
diabetes.   
 
Modes of Inhibition  
As illustrated in figure 1.10, inhibitors of FBPase can be separated into three 
different categories: those that inhibit at the substrate binding site, those that compete 
with AMP (1) for binding at the allosteric site and more recently, those that bind at a site 
at the FBPase subunit interface.   
 
Inhibitors that Bind at Active Site: Competitive Inhibitors 
Though it is commonplace to target the substrate-binding site when designing 
competitive inhibitors against enzymes, one can rarely find potent competitive inhibitors 
that bind at the FBPase active site. Compounds α- and β-D-arabinose 1,5-diphosphate (10 
and 11 respectively) were prepared in a stereoselective manner as analogs of β-D-fructose 
2,6-bisphosphate,70 the natural FBPase inhibitor.  The β-analog was found to have better 
affinity to rat liver FBPase with a Ki of 3.4 µM while the α-anomer inhibited the enzyme 
with an approximate Ki of 30 µM.71  
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This lack of progress in designing inhibitors that bind at the active site is largely 
attributed to the highly charged nature of the site and the challenges involved in 
designing suitable carbohydrate-based analogs that can compete effectively against 
elevated levels of the natural substrate.72  
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Figure 1.11. Structures of α- and β-D-arabinose 1,5-diphosphate (10 and 11 
respectively). 
 
Inhibitors that Bind at the ‘Novel’ Allosteric Site 
In 2002, Pfizer screened a library of compounds known to be enzyme inhibitors 
that compete with AMP and/or ATP, against pig kidney FBPase that led to the 
development of a series of anilinoquinazolines that are allosteric inhibitors of the 
enzyme.73 To better understand the mode of binding, one of the anilinoquinazolines 
analog (12, IC50 = 0.83 µM) was soaked with pig kidney FBPase crystals that were 
previously cocrystallized with a different inhibitor and 12 was revealed by X-ray 
crystallography to be binding at the symmetry-repeated novel allosteric site found at the 
subunit interface of the enzyme. Shortly after, Ontogen74 synthesized a highly 
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constrained pseudo-tetrapeptide – OC252-324 (13. IC50 = 1.87 µM), which was also seen 
in the crystal structure to occupy the new allosteric site located at the enzyme subunit 
interface.  In both structures, each inhibitor-type binds as a pair but the binding modes 
were different.   With 12, upon binding, the enzyme subunits were found to have rotated 
17° from their position in the catalytically active R state in the same manner as the AMP-
inhibited T state structure.  In the case of 13, the liganded complex adopted a quaternary 
structure between the R and T-states.  
 
With respect to inhibitors that bind at the above-described ‘novel’ allosteric site, 
no inhibition data beyond those performed in vivo have been described.  
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Figure 1.12. Examples of uncompetitive inhibitors that bind at the ‘novel’ allosteric site. 
 
Inhibitors that Bind at the AMP-Binding Site: Non-competitive Inhibitors 
The most common strategy for pursuing inhibitors against FBPase is to focus on 
the AMP binding site.  However, targeting the AMP binding site is challenging in its own 
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right.  An inescapable task is to identify novel inhibitors with high specificity for the 
AMP allosteric site of FBPase in the face of the plethora of AMP-binding enzymes 
controlling key biosynthetic pathways. One of the first inhibitors isolated that binds at the 
AMP allosteric site is 5-amino-4-imidazolecarboxamide riboside monophosphate (14, 
ZMP), a close analog of AMP.  ZMP is not a tight binding inhibitor of both rat and 
human FBPase with IC50 values of 370 µM75 and 12 µM respectively.76 In addition, ZMP 
has poor selectively for FBPase as it not only binds to but also activates AMP-activated 
protein kinase.75,77 In addition, ZMP was also found to modulate the activities of 6-
phosphofructo-2-kinase and glycogen phosphorylase.75,78 Aside from specificity issues, 
AMP binding sites are mostly hydrophilic in nature and have a high reliance on the 
negatively charged phosphate group of AMP for binding.79  
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Figure 1.13. Structure of 5-amino-4-imidazolecarboxamide riboside 
monophosphate, a close analog of AMP. 
 
In the discovery of inhibitors that bind at the AMP site, two strategies have been 
commonly used.  The first approach involves the high-throughput screening (HTS) of 
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existing compound libraries followed by lead optimization.  The second strategy involves 
structure-based drug design, often using AMP as the initial starting point.72  
 
Non-competitive Inhibitors from Structure-based Drug Design 
One of the most potent inhibitors that competes with AMP for binding is 
MB05032 (16) and its pro-drug CS-917 70 developed by Metabasis Therapeutics Inc.76 
MB05032 was designed by means of structure-based drug design with AMP serving as 
the starting point.  MB05032 inhibited human liver FBPase with an IC50 of 16 nM, 
representing a 60-fold improvement in potency over AMP.  More importantly, MB05032 
did not affect the activity of enzymes such as AMPK, glycogen phosphorylase or 
phosphofructokinase at concentrations greater than 1000-fold higher than the 1C50 value 
for human liver FBPase.  
 
The pro-drug CS-917 (15) was designed to aid cellular penetration and oral 
absorption, which were previously impeded by the dianionic nature of the phosphonate 
group in MB05032.  Initial clinical evaluation of CS-917 in overnight fasted healthy 
volunteers revealed encouraging tolerability and safety profiles.  Subsequent phase IIa 
trials conducted with patients with type 2 diabetes also proved safe and well tolerated.  In 
July 2007, Daiichi Sankyo – a strategic collaborator of Metabasis, advised the company 
that the results from the recently completed Phase 2b trial showed that CS-917 had failed 
to significantly lower the placebo-adjusted level of glycosylated hemoglobin (HbA1c), a 
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measure of glucose load, at either of the two doses tested.  The drug was subsequently 
pulled from clinical trials. 
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Figure 1.14. Examples of non-competitive inhibitors from structure-based drug design. 
 
Non-competitive Inhibitors from HTS and Lead Optimization 
 HTS by Wright et al80 from Pfizer led to the identification of a novel class of 
inhibitors against human liver FBPase.  These inhibitors possess a core indole carboxylic 
acid structure.  Analogs of the lead compound 17 were synthesized and the best inhibitor 
18 had an IC50 of 1.2 µM, a value that is comparable to that of AMP.  Inhibitor 17 was 
also co-crystallized with pig kidney FBPase and the indole ring of the inhibitor was 
observed to be occupying the same shallow hydrophobic pocket as the purine ring of 
AMP, with the indole nitrogen – N1 – making the same hydrogen bond with allosteric 
site residue T31 as the N1 of AMP.   No further optimization nor biological 
characterization of these inhibitors has been reported. 
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Figure 1.15. Non-competitive Inhibitors from HTS and Lead Optimization. 
 
More recently by Hebeisen et al.81 a HTS identified a hit cluster of aromatic 
sulfonylureas that bind to the AMP site.  Compound 18 is representative of this class and 
inhibits human liver FBPase with an IC50 of 1.6 µM.  Interestingly, when 18 was 
cocrystallized with human liver FBPase, Hebeisen et al. found the disulfide 19, between 
adjacent FBPase monomers, instead of the expected two molecules of 18.  This discovery 
led to the synthesis of a series of dual binding AMP site inhibitors that gained up to 105 
times potency over the initial lead compound. 
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Figure 1.16. Structure of the aromatic sulfonylureas (18) and the disulfide linked 
formed (19), identified by Hebeisen and co-workers. 
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Metabasis had recently launched the clinical development of a second-generation 
drug in the FBPase inhibitor class: MB07803.55 In a 12 Nov 2008 report by Reuters2, 
Metabasis announced that the company’s Phase 2a clinical trial for MB07803 had 
showed statistically significant reductions in fasting plasma glucose.  In addition, 
MB07803 was also found to be safe and well tolerated in this study. These promising 
results have prompted Metabasis to launch a corporate restructuring effort that will allow 
the company to focus on the development of MB07803 for the treatment of type-2 
diabetes. These efforts by Metabasis and other research groups continue to show that 
FBPase is important as a target in the discovery of direct inhibitors of glucose production.  
                                                
2  www.reuters.com/finance, “Metabasis Therapeutics, Inc. Announces Corporate Restructuring 
And Workforce Reduction”, 20 Jan, 2009  
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Figure 1.17.  Potential binding sites for inhibitors against FBPase.  Competitive 
inhibitors bind at the F16BP binding site while non competitive inhibitors bind within the 
AMP binding site and more recently, inhibitors that bind at the ‘novel’ allosteric site, 
located the FBPase subunit interface. (PDB code 1FRP)  
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1.8 Research Goals 
 
This research aims to design, develop and characterize inhibitors against ATCase 
and FBPase. Other than the obvious therapeutic significance, it also aims to provide new 
information about the mechanism of the respective enzymes.   
 
With ATCase, the objectives are firstly, to perform comprehensive structure-activity 
relationships (SAR) studies on the Asp moiety within PALA and document the effects these 
changes have on the overall activity of the molecule.  Secondly, this research also aims to 
develop potent and novel inhibitors that bear no structural resemblance to PALA. 
 
With FBPase, this research aims to develop novel and specific inhibitors that bind 
to the AMP allosteric site of the mammalian enzyme from both pig kidney and human 
liver.  New scaffolds will be explored through a virtual high-throughput screening 
(vHTS) system and by looking at natural products that have anti-diabetic properties.    
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2.1  Abstract 
 
Escherichia coli aspartate transcarbamoylase (ATCase) catalyzes the committed 
step in pyrimidine nucleotide biosynthesis, the reaction between carbamoyl phosphate 
(CP) and L-aspartate to form N-carbamoyl-L-aspartate and inorganic phosphate. The 
enzyme exhibits homotropic cooperativity and is allosterically regulated.  Upon binding 
L-aspartate in the presence of a saturating concentration of CP the enzyme is converted 
from the low-activity low-affinity T state to the high-activity high-affinity R state. The 
potent inhibitor N-phosphonacetyl-L-aspartate (PALA), which combines the binding 
features of Asp and CP into one molecule, has been shown to induce the allosteric 
transition to the R state. In the presence of only CP the enzyme is the T structure with the 
active site primed for the binding of aspartate.  In a structure of the enzyme•CP complex 
(TCP), two CP molecules were observed in the active site approximately 7Å apart, one 
with high occupancy and one with low occupancy. The high occupancy site corresponds 
to the position for CP observed in the structure of the enzyme with CP and the aspartate 
analog succinate bound. The position of the second CP is in an unique site and does not 
overlap with the aspartate binding site. As a means to generate a new class of inhibitors 
for ATCase, the domain-open T state of the enzyme was targeted. We designed, 
synthesized and characterized three inhibitors that were composed of two 
phosphonacetamide groups linked together.  These two phosphonacetamide groups 
mimic the positions of the two CP molecules in the TCP structure.  X-ray crystal 
structures of ATCase•inhibitor complexes revealed that each of these inhibitors bind to 
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the T state of the enzyme and occupy the active site area. As opposed to the binding of 
Asp in the presence of CP or PALA, these inhibitors are unable to initiate the global T to 
R conformational change. Although the best of these T-state inhibitors only has a Ki in 
the micromolar range, the structural information with respect to their mode of binding 
provides important information for the design of second generation inhibitors that will 
have even higher affinity for the active site of the T state of the enzyme. 
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2.2  Abbreviations 
 
E. coli aspartate transcarbamoylase; CP, carbamoyl phosphate; PALA, 
N-phosphonacetyl-L-aspartate; PAM phosphonacetamide; C1/C6, the two catalytic 
chains of ATCase in the asymmetric unit of the crystal;  R1/R6, the two regulatory chains 
of ATCase in the asymmetric unit of the crystal;  ASP domain, the portion of the catalytic 
chain of ATCase primarily involved in binding L-aspartate; CP domain, the portion of the 
catalytic chain of ATCase primarily involved in binding carbamoyl phosphate; Tapo, the 
X-ray structure of ATCase in the presence of CTP (PDB code: 1ZA1);  TCP, the T-state 
X-ray structure of the aspartate transcarbamoylase holoenzyme in the presence of CTP 
and CP (PDB code: 1ZA2); TPAM, the X-ray structure of ATCase in the presence of PAM 
(PDB code: 3AT1); RPM the X-ray structure of ATCase in the presence of PAM and 
malonate (PDB code: 7AT1); RPALA, the X-ray structure of ATCase in the presence of 
PALA (PDB code: 1D09); R236_PAM, the X-ray structure of D236A mutant ATCase in the 
presence of PAM (PDB code: 2A0F); T1, the T-state X-ray structure of the ATCase 
holoenzyme in the presence of CTP and 2,2'-(ethane-1,2-diylbis(azanediyl))bis(2-
oxoethane-2,1-diyl)diphosphonic acid (1); T2, the T-state X-ray structure of the ATCase 
holoenzyme in the presence of CTP and 2,2'-(1,3-phenylenebis(azanediyl))bis(2-
oxoethane-2,1-diyl)diphosphonic acid (2); T3, the T-state X-ray structure of the ATCase 
holoenzyme in the presence of CTP and 3,5-bis(2-phosphonoacetamido)benzoic acid (3) 
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2.3 Introduction 
 
Escherichia coli aspartate transcarbamoylase (E.C. 2.1.3.2, ATCase) catalyzes the 
committed step in pyrimidine nucleotide biosynthesis, the reaction between carbamoyl 
phosphate (CP) and L-aspartate to form N-carbamoyl-L-aspartate and inorganic 
phosphate. The reaction is ordered with CP binding before L-aspartate and N-carbamoyl-
L-aspartate leaving before inorganic phosphate.20 E. coli ATCase exhibits cooperativity 
with respect to the second substrate aspartate,21 and exerts allosteric control over the rate 
of pyrimidine nucleotide metabolism.  The enzyme is allosterically inhibited by the end 
products of the pathway, CTP82 and UTP in the presence of CTP83, and is allosterically 
activated by ATP,82 the product of the parallel purine nucleotide biosynthesis pathway.  
The homotropic and heterotropic properties of the enzyme are manifest by the ability of 
the enzyme to switch between a low-activity low-affinity T state and a high-activity high-
affinity R state. 
 
E. coli ATCase is composed of twelve polypeptide chains.  The six larger chains 
(Mr 34 000) are grouped into two trimers, and the six smaller chains (Mr 17 000) are 
grouped into three dimers. The active sites are located on the larger or catalytic chains, 
while the allosteric binding sites are located on the smaller or regulatory chains.  The 
catalytic trimers and regulatory dimers are stable independent of each other.  After 
separation the catalytic trimers and regulatory dimers still retain catalytic activity and 
ability to bind the regulatory nucleotides, respectively.  However, homotropic 
cooperativity is abolished.  
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 In mammalian cells, the first three steps in de novo pyrimidine nucleotide 
biosynthesis are catalyzed by CAD, a multienzyme complex composed of carbamoyl 
phosphate synthetase, ATCase and dihydroorotas.84 A sequence alignment of the catalytic 
chain of E. coli ATCase with the corresponding portion of CAD reveals that all the amino 
acids involved in substrate binding and catalysis are fully conserved.85 No structural data 
is available for the CAD complex; however, the structure of E. coli ATCase has been 
determined in the T and R states in the presence and absence of substrates, substrate 
analogs and nucleotide effectors.53,86-88 
 
For the E. coli enzyme, the binding of Asp to the enzyme•CP complex causes the 
two domains of the catalytic chain to close,88 which accelerates the reaction by 
approximation.  This mechanism holds for both the holoenzyme as well as the isolated 
catalytic subunit, and is hypothesized to occur in the ATCase portion of CAD as well. 
 
One of the best inhibitors of ATCase is N-phosphonacetyl-L-aspartate (PALA) 
(Ki 27 nM).37 Biochemical and structural studies have shown that the addition of PALA 
induces the allosteric transition of the enzyme from the T to the R structure.30,53,89 The 
tight binding of PALA is most likely due to its resemblance to the tetrahedral 
intermediate in the reaction.  Using the X-ray structure of the enzyme•PALA complex, it 
has been possible to replace PALA with the structure of the tetrahedral intermediate with 
little or no alterations to the positions of side chains in the active site.53  PALA has also 
been shown to be a good inhibitor of CAD in vitro90,91and has been shown to stop the 
proliferation of cancer cells in culture.92   
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Although the structure of the E. coli ATCase•PALA complex (RPALA) is in the R-
structural state, the X-ray structure of the E. coli ATCase•CP complex (TCP) is in the T-
structural state.88   In this structure, two molecules of CP are bound in each active site, 
one with full occupancy and the one with significantly lower occupancy. The high 
occupancy site corresponds to the position for CP observed in the structure of the enzyme 
with CP and the aspartate analog succinate bound.93 The position of the second CP is a 
unique site and does not overlap the aspartate binding site (see Figure 1). Since PALA 
contains in a single molecule the binding features of both aspartate and CP and is similar 
in structure to the tetrahedral intermediate of the reaction, PALA binds tightly to the 
domain-closed R state.  As a means to generate a new class of inhibitors of aspartate 
transcarbamoylase targeted at the domain-open T state of the enzyme, we designed, 
synthesized and characterized a series of compounds that were composed of two 
phosphonacetamide groups linked together.   The two phosphonacetamide groups mimic 
the positions of the two CP molecules in the TCP structure.  Our goal was to design 
inhibitors that would bind to the T state and thereby prevent the conversion of the 
enzyme to the R state, trapping the enzyme in the low-activity low-affinity T state. 
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2.4 Results 
 
Design and Modeling of Inhibitors 
  In the TCP structure of ATCase two molecules of CP are observed in the active 
site, one with full occupancy and one with significantly lower occupancy (see Figure 1).  
The position of these two CP molecules in the T-state active site suggested that a new 
class of T-state inhibitors of ATCase might be designed by linking two 
phosphonacetamide units together.  In the TCP structure the carbonyl carbons of CP are 
7.3 Å apart (see Figure 1).  Based on this separation distance, a number of inhibitor 
candidates were designed.  AUTODOCK was used to provide possible orientations of 
these inhibitors in the active site and to calculate their relative affinities for the enzyme.  
Scrutiny of the AUTODOCK results for 1 bound in the active site revealed that, if the 
aliphatic functionality that linked the two phosphonacetamide moieties was replaced with 
an aromatic ring, the resulting compound would not only be able to increase the 
hydrophobic interactions with the 260’s loop, but would also be able to improve the 
distance between the two carbonyls closer to the target distance of 7.3 Å.  True to our 
hypothesis, AUTODOCK results indicated that 2 and 3 had better binding energies than 
PALA in the T state.  Based upon these AUTODOCK results, inhibitor candidates 1, 2 
and 3 were synthesized (see Figure 2).   
 
Inhibitor Synthesis 
1a, 2a and 3a (Figure 2) were acylated with chloroacetic anhydride in the 
presence of pyridine94-96 to give 1b, 2b and 3b respectively.  Refluxing the acylated 
products at 140 °C in triethyl phosphite97 yielded 1c, 2c and 3c respectively. Final 
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compounds 1, 2 and 3 were deprotected using bromotrimethyl silane in a single pot at 
0°C respectively.98 
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Figure 2.1.  The active site of E. coli ATCase with CP bound.  Two molecules of CP are 
observed bound to each active site one with high affinity (CP1) and one with low affinity 
(CP2).  This distance between the carbonyl carbons of these two molecules is 7.3 Å.  This 
figure was drawn with POVScript+ 99 using the PDB entry 1ZA2. 
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Figure 2.2.  Synthetic scheme for inhibitors 1, 2 and 3: (i) (ClCH2CO)2O, pyridine, THF, 
0 °C - r.t., 18 h;  (ii) P(OEt)3, 140 °C, 6 h;  (iii) TMSBr, CH3CN, 0 °C - r.t., 18 h then 
H2O, r.t., 1 h. 
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Inhibition Studies 
Because of homotropic cooperativity and strong substrate inhibition, only IC50 
values could be determined for the ATCase holoenzyme. At pH 8.3 in 0.1 M Tris-acetate 
buffer the IC50 values for 1, 2 and 3 were 200 µM, 86 µM and 79 µM respectively.  More 
detailed kinetic characterization of the inhibitors was performed on the catalytic subunit 
with respect to both substrates, Asp and CP.  Inhibition constants were determined for 
compounds 1, 2 and 3, along with the known inhibitors PAM and PALA as controls. In 
these experiments 1 behaved differently than 2 and 3.  Compound 1 was a relatively weak 
inhibitor (see Table 2) and exhibited non-competitive inhibition with respect to both Asp 
and CP, 2 and 3 had Ki values approximately 10-fold lower than 1 and both exhibited 
competitive kinetics with respect to both Asp and CP. The Ki values for the inhibition of 
the catalytic subunit with respect to CP by 1, 2 and 3 were 2160 µM, 420 µM and 250 
µM respectively, as compared to 5820 µM for PAM and 0.033 µM for PALA (see Table 
2).  Both 2 and 3 showed lower Ki values than 1, and 3 exhibited a slightly lower Ki value 
than 2, in good agreement with our design rationale.   
 
X-ray structures of aspartate transcarbamoylase in the presence of 1, 2, and 3 
To better understand the mode of binding and any structural changes caused by 
the inhibitors, X-ray crystallography was employed.  Crystals of the enzyme in the 
presence of 1, 2 and 3 diffracted to a maximal resolution of 2.0, 2.0 and 2.5 Å, 
respectively, in the P321 space group. The unit cell dimensions a = b = 120.59, c = 
141.71 for 1, a = b = 119.94, c = 141.97 for 2, and a = b = 120.90, c = 141.61 for 3 
(Table 1) are very similar to those observed for the crystals of the enzyme in the absence 
of CP (Tapo, a = b = 120.29, c = 142.55 PDB code 1ZA1). Details of the data collection 
and refinement of these three structures can be found in Table 1. 
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The similarity in unit cell dimensions between T1, T2, T3 and Tapo structures 
suggests that the T1, T2 and T3 structures were in the same quaternary structure as the 
Tapo. In order to determine more accurately the quaternary conformation of the T1, T2 and 
T3 structures, the vertical separation between the upper and lower catalytic subunits for 
each structure was determined.100 The vertical separations for the T1, T2 and T3 structures 
were 45.55 Å 44.89 Å and 45.25 Å respectively.  This compares to the vertical separation 
of the T state derived from the Tapo, TCP and RPALA structures of 45.5 Å, 45.9 Å and 56.2 
Å respectively.  The vertical separation of T1, T2 and T3 structures is evidence that these 
three structures are globally in the T-quaternary conformation.  Although the binding of 
PALA to ATCase induces the T to R transition none of these inhibitors causes the 
quaternary conformational change.  Since these inhibitors were soaked into T-state 
crystals it may be argued that crystal-packing forces hold the enzyme in the T-state, 
however, when T-state crystals are soaked with PALA the crystal disintegrates within a 
few seconds (unpublished observation). 
 
 The T1, T2 and T3 structures were compared to the Tapo and TCP structures.  
Overall the T1, T2 and T3 tertiary structures were closer to the Tapo than the TCP structure.  
For example, the C1 and C6 catalytic chains of the T1 structure compared to the same 
chains of the Tapo structure had RMS deviations of 0.259 Å2 and 0.304 Å2 respectively, 
whereas when compared to the same chains in the TCP structure the RMS deviations were 
0.987 Å2 and 0.915 Å2 respectively.  The trend was the same for T2 and T3 structures as 
well.  The 80’s loop of both chains in the asymmetric unit in the T2 and T3 structures, 
were in a novel conformation, unlike that of either the 80’s loop conformation in the Tapo 
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or the TCP structures with largest differences seen between the T1 and TCP structures (see 
Figure 3, T1-A, T3-A). 
 
Coordination of the inhibitors in the active site of the T1, T2 and T3 structures 
The coordination of the phosphonacetamide group of 1, 2 and 3 that most closely 
matched the position of CP or PAM in the active site was different than the coordination 
of CP and PAM in the TPAM and TCP structures.  The most noteworthy differences were 
the hydrophobic interactions between Pro266 (not shown) and His134 and the phenyl 
ring of 2 (Figure 3B, T2-B), and the absence of backbone interactions to 3 from Leu267, 
Pro266 and Arg54 (Figure 3, T3-B). 
 
Noteworthy in all three structures, is an interaction between the inhibitor and 
Thr168, a residue that has not been observed to interact with substrate or substrate 
analogs in other ATCase structures (Figure 3B).  In the T3 structure Lys84, from an 
adjacent catalytic chain interacts with the carboxylate (Figure 3, T3-B).  In previous 
structures Lys84 only interacts with substrates or substrate analogs in the R state.  
Finally, Arg296 which does not interact with substrates or substrate analogs in structures 
of the wild-type enzyme in the T state interacts with 3 (Figure 3, T3-B). 
 
In addition to a more open conformation of the T-state active sites, there are some 
positional changes in active site residues when compared to TPAM and TCP. The largest 
backbone differences in the active site besides Lys84 in the T3 structure are residues in 
the 50’s region from Glu50 to Thr55.  In the TCP and TPAM structures Thr53 forms a 
backbone interaction with the substrate or substrate analog, however, this interaction is 
not observed in any of the inhibitor structures reported here (Figure 3B).  
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3 binds more tightly to the enzyme than 1 or 2 
The presence of the hydrophobic phenyl “connector” ring between the two 
phosphonacetamide moieties of 2 and 3 hold the phosphate groups in a more rigid 
conformation, thus enhancing coordination in the ASP domain.  For example in the T3 
structure, 3 is coordinated by five interactions involving Arg229, Thr168 at hydrogen 
bonding distances less than 2.75 Å, significantly tighter interactions in the ASP domain 
than for structures 1 and 2.  The addition of the carboxylic acid also contributes to the 
binding of 3 by a specific interaction with Lys84 from the adjacent chain (Figure 3, T3-
B).  Figure 3C shows the two CP molecules in the active site of the TCP structure overlaid 
onto inhibitors 1, 2, and 3.   This figure presents the differences in orientation of the 
phosphonactemide moieties of the three inhibitors as compared to the two CP molecules 
in the active site. 
 
Additionally, significant side chain positional differences are seen in the CP and 
ASP domain when inspecting T1, T2, or T3 active sites with TCP overlaid, with the largest 
differences in TCP and T3 overlay, most likely induced by the enhanced binding of the 
phosphonacetamide moiety of 3 (Figure 4). 
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________________________________________________________________________ 
Table 2.1.  Data collection and refinement statistics for the T1, T2 and T3 Structures 
 
Data collection 1 2 3 
Space Group P321 P321 P321 
Cell Dimensions    
 a = b, c (Å) 120.59, 141.71 119.94, 141.97 120.90, 141.61 
 α, β, γ (°) 90, 90, 120 90, 90, 120  90, 90, 120  
Resolution (Å) 27.35-2.00 28.23-2.00  28.45-2.50  
Rmerge
a (%) .058 (.362)  .097 (.390)  .075 (.370)  
Average (I/σ) 13.5 (4.3) 9.7 (3.9)  13.0 (3.9) 
Completeness (%) 99.9 (99.5) 99.8 (99.6)  99.1 (100)  
Total Reflections 428,691  369,064  206,097 
Unique reflections 80,677 79,872 80,627  
Redundancy 5.31 (5.13) 4.62 (4.24)  4.96 (4.78) 
Refinement  
Resolution (Å) 27.35-2.10 28.23-2.25  28.45-2.50  
Reflections 80,493 65,470 80,627 
Rfactor/Rfree .190/.255 .207/.249  .210/.240 
RMS deviations   
Bonds (Å) .008 .011   .010 
Angles (°) 1.57 1.90   1.54   
Mean B value (Å2)  40.8 45.9   42.3  
Total number waters 790 252   391  
Values in parentheses are for the highest resolution shell 
a 
! 
Rmerge =
| Ihkl "  Ihkl# |
Ihkl#
! ! 
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Table 2.2. Characterization of Inhibitors a 
 
Compound Structure Distance 
(Å) 
KICP 
(µM) 
 
KIAsp 
(µM) 
 
CP 
NH2O
P
O
O
HO
OH
 
7.3 b --- --- 
PAM 
NH2C
H2
P
O
O
HO
OH
 
--- 5820  
(1370) 
3870  
(560) 
PALA 
N
H
P
O
O
HO
OH
COOH
COOH
 
--- 0.033  
(0.003) 
0.021  
(0.001) 
1 
N
H
H
NP
P
O
O
O
OHO
OH
HO
OH
 
6.0 c 2160  
(440) 
1990  
(116) 
2 H
N
H
N
H
P P
O O
O O
HO
OH HO
OH
 
7.0 c 420  
(32) 
420  
(11) 
3 H
N
H
N
COOH
P P
O O
O O
HO
OH HO
OH
 
7.0 c 250  
(20) 
310 
 (8) 
aKICP and KIAsp values were determined colorimetrically101 at pH 7.0 in 50 mM Hepes 
buffer at a fixed concentration of 10 mM Asp and 0.4 mM CP, respectively.  Numbers in 
parenthesis correspond to error estimates. bDistance between the carbonyl carbons of the 
two CP molecules in the active site of the TCP structure (see Figure 1).  cDistance between 
the two carbonyl carbons in an extended conformation of the inhibitor. 
   68 
 
 
 
Figure 2.3. (A) Representation of two adjacent catalytic chains (C1 and C2) of ATCase 
that comprise one active site.  Shown is a cartoon representing the change between the 
TCP structure and the structure with the corresponding inhibitor bound. The width of the 
tube is proportional to the RMS deviation of the α-carbon atom positions. Also shown is 
the 80’s loop from the adjacent catalytic chain that contributes residues to the active site 
(80’s Loop*) colored in green with the largest differences in the loop colored in magenta.  
Other regions of notable difference in the α-carbon atom positions of the C1 catalytic 
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chain are residues 50-58, 229-233, and 266-271 (pink). This figure was drawn with 
CHIMERA102  (B) Close-up of the active sites of the T1, T3 T2 structures showing the 
2Fo–Fc electron density maps contoured at 1.8 σ (blue). Also shown are simulated 
annealing 2Fo–Fc electron density maps, contoured at 1.2 σ, with 1, 2, and 3 omitted from 
the map calculation (magenta).  Overlaid onto the electron density maps are the refined 
positions of the residues.  (C) Overlay of the TCP active site88 showing the two CP 
molecules (CP1 and CP2), and the T1, T2 and T3 active sites showing the inhibitors 1, 2 
and 3.  This figure was drawn with POVScript+ 99. 
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Figure 2.4.  Stereoview of the active site of ATCase.  Overlay of the TCP (thin, black) 
onto T3 (thick, grey). This figure was drawn with POVScript+ .99 
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Determination of the Quaternary Structure of  the Enzyme in the Presence of 1, 2 and 3 
  Using a pyrene-labeled version of ATCase it is possible to use fluorescence 
spectroscopy to determine if substrates or inhibitors are able to convert ATCase from the 
T to the R state.103 This is made possible by the selective attachment of pyrene at position 
241 in the catalytic chain.  In the T state the pyrene labels in the C1 and C4 catalytic 
chains are far apart, while in the R state, after the allosteric transition, they are close 
together.  When two pyrenes are within ~5-10 Å of each other they show excimer 
emission.104 Thus, in the T state there is no excimer emission while in the R state there is 
substantial excimer emission with a corresponding decrease in monomer emission.  
Shown in Figure 5A are the emission spectra of ATCase in absence (T-state) and 
presence of PALA (R-state).  Upon adding PALA, the excimer peak at 490 nm increases 
dramatically, while the monomer peak (~400 nm) decreases.  However, the addition of 1, 
2 or 3 did not cause any increase in excimer fluorescence at 490 nm indicating that these 
inhibitors cannot convert the enzyme to the R-state. 
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Figure 2.5.  Fluorescence emission spectra of the pyrene-labeled ATCase. (A) ATCase 
(1 µM) in the absence (thin line) and in the presence of 1 µM PALA (heavy line). (B) 
ATCase in the presence of 1000 µM 1 (dotted line), 660 µM 2 (thin line) and 600 µM 3 
(heavy line).   
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2.5 Discussion 
 
Figure 6A shows the Tapo active site of ATCase with two molecules of CP bound.  
Our goal in this project was to design, synthesize and characterize both functionally and 
structurally a series of compounds that would completely fill the more open T-state active 
site of ATCase than the closed R-state active site, and thus potentially lock the enzyme in 
the low-activity low-affinity T state.  When 1, 2 and 3 bind to ATCase the enzyme 
remains in the quaternary T structure as determined by both fluorescence measurements 
with the pyrene-labeled enzyme in solution (Figure 5), and by X-ray crystallography of 
the enzyme•inhibitor complexes.  
 
The three inhibitors designed as 1, 2 and 3, each bind in the T-state active site and 
fill the active site pocket.  As an example, Figure 6B shows 3 bound in the active site 
based upon the T3 structure.  The change of aliphatic functionality connecting the 
phosphonacetamide groups in 1 to the phenyl moieties in 2 and 3 (see Table 2) enhances 
binding by promoting hydrophobic interactions with Pro266, Leu267 and Pro268.  This 
enhanced binding and specificity was reflected in the significantly lower Ki values of 2 
and 3 as compared to 1.  In addition, the lower Ki value of 3 over 2 can be attributed to 
the additional carboxylate functionality, which promotes coordination of 3 with Lys84 
from an adjacent catalytic chain (see Figure 4 and 6B).  The T3 structure also represents 
the first instance in which Lys84 from an adjacent chain has been observed to be 
coordinating a substrate or a substrate analog in a T-state structure. 
 
Although 2 and 3 are reasonably good inhibitors of ATCase, none approaches the 
potency of PALA. This apparent inconsistency is due to the difference in the mode by 
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which these inhibitors bind.  When CP binds it induces conformational changes that 
enhance its binding, an induced fit.  This alteration in protein structure can be observed 
by comparing the Tapo and TCP structures.88 An induced fit also occurs when PAM binds, 
but the extent of the conformational change is significantly smaller than when CP 
binds.105  The extent of the induced fit is even more extreme for PALA, since PALA 
binding results in the closure of the two domains of the catalytic chain, which occurs in 
conjunction with the T- to R-quaternary conformational change.53  PALA binds in a tight 
complex to the R-quaternary of the enzyme, while weak binding of PAM and CP alone, 
is to the T-quaternary structure.  The tertiary and quaternary conformations of the T1, T2 
and T3 structures are actually closer to the Tapo structure than the TCP structure, 
suggesting that the binding of these inhibitors, even though they contain a 
phosphonacetamide functionality cannot produce the same conformational change 
induced by the binding of the natural substrate CP or the substrate analog PAM. Whereas 
the binding of CP weakens interactions that are required for the stabilization of the 
enzyme in the T-state, with side chains of the active site approaching their R-state 
conformation, inhibitors 1, 2 and 3 never access the high-affinity R-state active site.  A 
consequence of binding of these inhibitors to the T state is to cause the 80’s loop to adapt 
an alternate conformation not observed with the natural substrates.  When these inhibitors 
fill the T-state active site they do prevent the quaternary conformational change to the R 
state. 
 
The active site of the T1, T2 and T3 structures suggest a mechanism for inhibition of 
domain closure.   
Inspection of active sites of the T1, T2 and T3 structures indicates that there are 
significant differences in how the phosphonacetamide moiety binds as compared to how 
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this moiety binds in the TPAM and RPM structures.105 In the T3 structure these differences 
are most pronounced and include omission of key interactions between 3 and the 
backbone carbonyls of Pro266 and Leu267 (Figure 3, T3-B), a new interaction between 
Arg296 and the phosphate oxygens of 3, and an interaction with Lys84 from an adjacent 
catalytic chain with the phenyl carboxylate of 3 (Figure 3, T3-B).   
 
Arg296 has not been observed to interact with substrates or substrate analogs, 
however it has been observed to interact with PAM in the R236_PAM structure.106  Arg296 
is held in position by hydrogen bonding interactions with Thr55 and Ser58 of the 50’s 
loop and Thr136, a residue on the cusp of the CP/Asp domains.  Arg296 may function in 
a number of roles including, (i) an initial interaction with carbamoyl phosphate in the 
active site before the induced fit, (ii) in stabilizing the position of the 50’s loop, and (iii) 
in helping correctly position CP for the nucleophilic attack by the α-amino group of 
aspartate.106 The role of Arg296 may be more important for the function of ATCase than 
previously thought, since a sequence alignment of a number of transcarbamoylase genes 
indicated that this residue is conserved.  The exact functional role of Arg296 must await 
direct verification by site-specific mutagenesis. In the T3 structure, Arg296 is 
coordinating one of the phosphate oxygens of 3 (Figure 3, T3-B), instead of the carbonyl 
oxygen of PAM as seen in the R236_PAM structure.  This interaction may prevent the 
binding of phosphoacetamide moiety of 3 in the proper orientation to induce the 
conformational changes that are observed when PAM binds.105   
 
As observed in the TCP structure, critical for the preparation of the high affinity 
Asp binding site is the movement of the adjacent catalytic chain 80’s loop towards the 
active site pocket to create the necessary electropositive environment for Asp binding.88 
   76 
The novel conformation of the 80’s loop seen in the T1, T2 and T3 structures does not 
create the necessary electropositive environment for Asp binding. These data indicate that 
inhibitors 1, 2 and 3 have the effect of keeping the architecture of the active site in the 
open conformation rather than promoting the induced fit observed with the natural 
substrates.  
 
This new class of ATCase inhibitors function by binding to the T-structure and 
inhibiting the enzyme by filling the T-structure active site.  However, as opposed to the 
binding of CP or PALA, these inhibitors are unable to initiate the conformational change 
that reorients the active site residues for high-affinity binding.  Furthermore, without the 
induced fit that normally occurs upon the binding of CP, the electrostatic environment of 
the active site is different than observed with the natural substrates (or substrate analogs 
like PALA).  Although 2 and 3 are reasonably good inhibitors of ATCase, these data 
suggest how the structure of these molecules could be modified in order to produce even 
more potent inhibitors.  Using structural studies of these second generation inhibitors it 
should be possible to develop even more potent inhibitors of the ATCase. 
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Figure 2.6.  (A) Close-up of the active site of TCP structure (C1 and C2 catalytic chains)88 
showing the position of the two CP molecules in a space-filling representation. (B) Close-
up of the active site of T3 structure (C1 and C2 catalytic chains) showing the position of 
the 3 molecules in a space-filling representation. The TCP and T3 structures were overlaid 
prior to calculating the surfaces. This figure was drawn with CHIMERA102. 
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2.6 Experimental 
 
Chemicals 
CTP, L-aspartate, potassium dihydrogen phosphate and sodium dodecyl sulfate 
were obtained from Sigma Chemical Co. (St. Louis, Missouri). Carbamoyl phosphate 
dilithium salt, obtained from Sigma, was purified before use by precipitation from 50% 
(v/v) ethanol and was stored desiccated at –20°C107. The 2-mercaptoethanol and the 
chemicals used in preparation of the inhibitors were purchased from Aldrich (St. Louis, 
Missouri). 
 
NMR 
 1H, 13C, 31P NMR spectra were recorded on Varian Gemini 2000 (400 MHz and 
300 MHz) spectrometers. 1H chemical shifts (δ) are reported in ppm downfield of an 
internal standard of tetramethylsilane (TMS, δ 0.00) or with the solvent references 
relative to TMS employed as the internal standard (DMSO-d6, δ 2.50; D2O, δ 4.79).  13C 
and 31P chemical shifts are reported with DMSO-d6 and 85 % H3PO4 as references 
respectively. ESI mass spectrometry was performed at the Mass Spectrometry Facility, 
Boston College. 
 
Synthesis and Characterization of 2,2'-(ethane-1,2-diylbis(azanediyl))bis(2-oxoethane-
2,1-diyl)diphosphonic acid (1)  
 N,N'-(ethane-1,2-diyl)bis(2-chloroacetamide) (1b).  Ethane-1,2-diamine (1a) (500 
mg, 8.3 mmol) was dissolved in anhydrous CH2Cl2 (8 mL) and the solution was cooled to 
0 oC.  Pyridine (3.4 mL, 42 mmol) was added to 1a dropwise and stirred at 0 °C for 5 
min.   Chloroacetic anhydride (6 g, 42 mmol) was dissolved in anhydrous CH2Cl2 (10 
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mL) and the solution was added to the reaction mixture via a double-edged needle, under 
anhydrous conditions. The mixture was allowed to warm to room temperature, and was 
stirred for 18 h.  The dark brown precipitate that formed in the reaction vessel after 18 h 
was collected under vacuum filtration and washed with excess CH2Cl2 and H2O to yield 
1b (957 mg, 54.3%, white, powdery solid). 1H NMR ((CD3)2SO, 400MHz) δ 8.28 (br. s 
2H), 4.05 (s, 4H), 3.17 (d, J = 2.8 Hz, 4H); 13C NMR ((CD3)2SO, 100MHz) δ 165.85, 
42.60, 38.80. ESI-MS (m/z) 236.9 [M + Na]+. 
 
Tetraethyl 2,2'- (ethane-1,2-diylbis(azanediyl))bis (2-oxoethane-2,1-diyl) 
diphosphonate (1c).  Excess triethyl phosphite (11 mL) was added to 1b (700 mg, 3.28 
mmol) and the reaction was refluxed at 140 °C for 6 h.  A white precipitate formed upon 
cooling of the reaction mixture to room temperature.  Excess triethyl phosphite was 
decanted and the precipitate was washed with excess hexane to remove all traces of 
triethyl phosphite to yield 1c (950 mg, 69%, fine, white solid). 1H NMR ((CD3)2SO, 
400MHz) δ 7.75 (br. s 2H), 4.17 (q, J = 6.8 Hz, 8H), 3.36 (d, J = 5.6 Hz, 4H), 2.88 (d, J = 
21.2 Hz, 4H), 1.36 (t, J = 7.1 Hz, 12H); 13C NMR ((CD3)2SO, 100MHz) δ  165.47, 63.08, 
36.81, 35.50, 17.72; 31P NMR ((CD3)2SO, 121MHz) δ 23.62 . ESI-MS (m/z) 417.0 [M + 
H]+. 
 
2,2'-(ethane-1,2-diylbis(azanediyl))bis(2-oxoethane-2,1-diyl)diphosphonic acid 
(1).   1c (700 mg, 1.6 mmol) was dissolved in CH3CN (5 mL) and the solution was 
cooled to 0 °C.  Bromotrimethyl silane (1.4 mL, 10.4 mmol) was then added dropwise.  
The mixture was allowed to warm to room temperature and stirred for 18 h.  Excess 
solvent was removed under vacuum resulting in a viscous liquid, to which H2O (3 mL) 
was added and the reaction was allowed to stir at room temperature for 1 h.  The mixture 
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was washed with CH2Cl2 (3 x 10 mL) and the aqueous layer was collected and 
lyophilized to yield 1 (400 mg, 82%, white solid). 1H NMR (D2O, 400 MHz) δ 4.80 (s, 
2H), 3.33 (s, 4H), 2.84 (d, J = 21.2 Hz, 4H); 31P NMR (D2O, 121MHz) δ 18.458. ESI-MS 
(m/z) 304.9 [M + H]+ 
  
Synthesis and Characterization of 2,2'-(1,3-phenylenebis(azanediyl))bis(2-oxoethane-2,1-
diyl)diphosphonic acid (2) 
N,N’-(1,3-phenylene)bis(2-chloroacetamide) (2b). Benzene-1,3-diamine (2a) 
(1.5g, 8.2 mmol) was dissolved in anhydrous DMF (10 mL) and the solution was cooled 
to 0 °C.  Pyridine (3.3 mL, 41 mmol) was added to 2a dropwise and stirred at 0 °C for 5 
min. Chloroacetic anhydride (5.8 g, 41 mmol) was dissolved in anhydrous DMF (10 mL) 
and the solution was added to the reaction mixture via a double-edged needle, under 
anhydrous conditions.  The mixture was allowed to warm to room temperature and was 
stirred for 18 h.  CH2Cl2 was added to the reaction mixture and bright, yellow precipitate 
formed.  The precipitation was collected under vacuum filtration and was washed with an 
excess CH2Cl2 to yield 2b. (1g, 46.7%, white, powdery solid). 1H NMR ((CD3)2SO, 
400MHz) δ 10.36 (s, 2H), 7.95 (s, 1H), 7.34-7.28 (m, 3H), 4.25 (s, 4H); 13C NMR 
((CD3)2SO, 100MHz) δ 164.39, 138.64, 129.02, 114.66, 110.18, 43.59. ESI-MS (m/z) 
282.9 [M + Na]+.  
 
Tetraethy 2,2'-(1,3-phenylenebis(azanediyl))bis(2-oxoethane-2,1-diyl)diphos-
phonate   (2c).   
Excess triethyl phosphite (10 mL) was added to 2b (1g, 3.8 mmol) and the 
reaction was refluxed at 140 °C for 6 h.  Excess triethyl phosphite was removed under 
reduced pressure to give a yellow, viscous residue, which was further purified by column 
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chromatography using a solvent mixture of CH3OH/ethyl acetate (1:9) to yield 3c (1 g, 
56%, white solid). 1H NMR ((CD3)2SO, 400MHz) δ  10.15 (s, 2H),  7.88 (s, 1H), 7.25-
7.20 (m, 3H), 4.06 (q, J = 6.8, 8H), 3.08 (d, J = 21.6, 4H), 1.24 (t, J = 7.2, 12H); 13C 
NMR ((CD3)2SO, 100MHz) δ  162.66, 139.00, 128.83, 113.96, 109.58, 61.71, 36.51, 
35.21, 16.25; 31P NMR ((CD3)2SO, 121MHz) δ  22.58. ESI-MS (m/z) 487.2 [M + Na]+. 
 
2,2'-(1,3-phenylenebis(azanediyl))bis(2-oxoethane-2,1-diyl)diphosphonicacid (2).  
2c (600 mg, 1.283 mmol) was dissolved in CH3CN (6 mL) and the solution was cooled to 
0 °C.  Bromotrimethyl silane (1.08 mL, 8.3 mmol) was then added dropwise.  The 
mixture was allowed to warm to room temperature and stirred for 18 h.  Excess solvent 
was removed under vacuum resulting in a viscous liquid, to which H2O (3 mL) was 
added and the reaction was allowed to stir at room temperature for 1 h.  The mixture was 
washed with CH2Cl2 (3 x 20 mL) and the aqueous layer was collected and lyophilized to 
yield 2 (453 mg, 99%, light brown solid). 1H NMR (D2O, 300MHz) δ 7.59 (s, 1H), 7.41-
7.35 (m, 1H), 7.27-7.24 (m, 2H), 2.98 (d, J = 21, 4H); 31P NMR (D2O, 121MHz) δ 23.24. 
ESI-MS (m/z) 375.0 [M + Na]+. 
 
 
Synthesis and Characterization of 3,5-bis(2-phosphonoacetamido)benzoic acid (3) 
3,5-bis(2-chloroacetamido)benzoic acid (3b).   3,5-diaminobenzoic acid 3a (2g, 
13 mmol) was dissolved in anhydrous DMF (10 mL) and the solution was cooled to 0 °C.  
Pyridine (5.2 mL, 65 mmol) was added to 3a dropwise and stirred at 0 °C for 5 min.   
Chloroacetic anhydride (8.9 g, 65 mmol) was dissolved in anhydrous DMF (10 mL) and 
the solution was added to the reaction mixture via a double-edged needle, under 
anhydrous conditions.  The mixture was allowed to warm to room temperature, and was 
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stirred for 18 h.  CH2Cl2 was added to the reaction mixture and a bright, yellow 
precipitation formed.  The precipitation was collected under vacuum filtration and was 
washed with excess CH2Cl2 to yield 3b (900mg, 37%, yellow, powdery solid).  1H NMR 
((CD3)2SO, 400MHz) δ 10.55 (s, 2H), 8.188 (s, 1H), 7.95 (s, 2H), 4.27 (s, 4H); 13C NMR 
((CD3)2SO, 100MHz) δ  166.44, 164.65, 138.85, 131.61, 115.28, 43.54.  
 
3,5-bis(2-(diethoxyphosphoryl)acetamido)benzoic acid (3c). Excess triethyl 
phosphite (10 mL) was added to 3b (900 mg, 4.3 mmol) and the reaction was refluxed at 
140 °C for 6 h. Excess triethyl phosphite was removed under reduced pressure to give a 
yellow, viscous residue, which was further purified by column chromatography using a 
solvent mixture of CH3OH/ethyl acetate (3:7) to yield 3c (1.7 g, 78%, white, flaky solid). 
1H NMR ((CD3)2SO, 300MHz) δ 10.88 (s, 2H), 8.10 (s, 1H), 7.92 (s, 2H), 4.07 (q, J = 7.4 
Hz, 8H), 3.10 (d, J = 21.6 Hz, 4H), 1.25 (t, J = 7.1 Hz, 12H); 13C NMR ((CD3)2SO, 
100MHz) δ 165.00, 163.07, 139.33, 130.54, 114.37, 61.80, 36.57, 35.28, 16.24, 14.23; 
31P NMR ((CD3)2SO, 121MHz) δ 22.91. 
 
3,5-bis(2-phosphonoacetamido)benzoic acid (3).   3c (200 mg, 0.39 mmol) was 
dissolved in CH3CN (4 mL) and the solution was cooled to 0 °C.  Bromotrimethyl silane 
(0.33mL, 2.5 mmol) was then added dropwise.  The mixture was allowed to warm to 
room temperature and stirred for 18 h.  Excess solvent was removed under vacuum 
resulting in a viscous liquid, to which H2O (3 mL) was added and the reaction was 
allowed to stir at room temperature for 1h.  The mixture was extracted with CH2Cl2 (3 x 
10 mL) and the aqueous layer was collected and lyophilized to yield 3 (100 mg, 65%, 
light brown solid). 1H NMR (D2O, 400MHz) δ 10.39 (s, 2H), 8.19 (s, 1H), 7.92 (s, 2H), 
3.00 (d, J = 20.8 Hz, 4H); 31P NMR (D2O, 121MHz) δ 23.24. 
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Enzyme Preparation 
E. coli ATCase holoenzyme and catalytic subunit were overexpressed utilizing E. 
coli strain EK1104  (F- ara, thi, δ(pro-lac), δpyrB, pyrF±, rpsL)108 containing plasmids 
pEK152109 and pEK17,108 respectively. The isolation and purification were as described 
previously.108 The concentration of the holoenzyme and catalytic subunit was determined 
by A280 based upon extinction coefficients of 0.59 cm2 mg-1 and 0.72 cm2 mg-1 
respectively.110 The purity of the enzymes were checked by SDS-PAGE111 and 
nondenaturing PAGE.112,113  
 
Crystallization and Freezing of Crystals 
ATCase holoenzyme was crystallized by microdialysis, using 50 µL wells. The 
enzyme solution, at ~18 mg/mL, was dialyzed against a solution of 40 mM citric acid, 3 
mM sodium azide, 1 mM 2-mercaptoethanol, 1 mM cytidine 5’-triphosphate, 0.2 mM 
EDTA (pH 5.7) as previously described.114 Crystals grew to average dimensions of 0.5 x 
0.5 x 0.1 mm within 2 weeks.  For the structure determination in the presence of 
inhibitors, enzyme crystals in a microdialysis chamber were dialyzed over 12 h against 
crystallization buffer containing 5 mM inhibitor. Crystals were then transferred into a 
freezing solution containing 30% 2-methyl-2,4-pentanediol in crystallization buffer with 
5 mM inhibitor for approximately one minute prior to freezing in liquid nitrogen.   
 
X-ray Data Collection and Processing 
The data for the structure for the three enzyme-inhibitor structures were collected 
using a Rigaku/MSC R-axis IV++ detector while X-rays were generated using a 
Rigaku/MSC RU-200 rotating-anode generator operating at 50 kV and 100 mA at the 
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Crystallographic Facility in the Chemistry Department of Boston College. The diffraction 
data were integrated, scaled and averaged using d*TREK.115 
 
Structural Refinement 
The initial model for the T1, T2 and T3 structures was derived from the 
coordinates of the Tapo and TCP structure.  Prior to refinement, all the waters and ligands 
were removed.  The refinement was carried out using CNS.116 After initial rigid body, 
simulated annealing, minimization, and B-factor refinement, initial maps were inspected. 
The 80’s loop of the catalytic chain was disordered; through several rounds of manual 
rebuilding the catalytic chain was corrected using XtalView.117 Several cycles of 
corrections were made to the regulatory chains by repeatedly overlaying the previously 
published T-state structure, Tapo.  After rebuilding of the 80’s loop and 240’s loop of the 
catalytic chains, the inhibitors were fit into the difference density in the active site.  Once 
manual rebuilding was complete, the placement of inhibitors was checked by simulated 
annealing omit maps calculated in CNS.116 
 
Waters were added to the structure using CNS and XtalView on the basis of Fo–Fc 
electron density maps at or above the 2.5 σ level, and were checked and retained only 
when they could be justified by hydrogen bonds.   The model was checked for errors 
using PROCHECK.118 The details of data processing and refinement statistics are given 
in Table 1. 
 
Automated Docking Procedure 
The program AUTODOCK119 was used for the automated docking of inhibitors to 
the active site.  AUTODOCK was used both in the design of the inhibitors, and as an aid 
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in the placement of the inhibitors in the difference density of the final models.  In order to 
have one complete active site, two adjacent catalytic chains were used for the docking 
procedure.  The grid box was set at 30 Å3 centered at the middle of the active site, with a 
grid spacing of 0.275 Å between grid points.  In each case, 50 docking runs were 
performed using the Genetic Algorithm with a maximum of 500,000 energy evaluations.   
 
Fluorescence Measurements 
In order to determine if the inhibitors 1, 2 and 3 were able to convert the enzyme 
from the T to the R state in solution fluorescence spectroscopy was employed in 
conjunction with a pyrene-labeled version of ATCase that is sensitive to the quaternary 
structure of the enzyme.103 Fluorescence emission spectra were recorded at 20° ± 1 C in 
50 mM Tris-acetate buffer, pH 8.3 on a Shimadzu 1000 spectrofluorimeter.  The 
excitation wavelength was 338 nm; the emission wavelength collected was 350–600 nm; 
the excitation and emission bandwidths were set to 5 nm. 
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3.1 Abstract 
 
A series of inhibitors of the aspartate transcarbamoylase, an enzyme involved in 
pyrimidine nucleotide biosynthesis, has been synthesized.  These inhibits are analogues 
of a highly potent inhibitor of this enzyme, N-phosphonacetyl-L-aspartate (PALA).  
Analogues have been synthesized with modifications at the α and β carboxylates as well 
as at the aspartate moiety. The ability of these compounds to inhibit the enzyme was 
evaluated.  These studies, with functional group modified PALA derivatives, showed that 
amide groups can be a useful substitute of the carboxylate in order to reduced the charge 
on the molecule, and indicate that the relative position of the functional group in the β-
position is more critical than the nature of the functional group. Some of the molecules 
synthesized here are potent inhibitors of the enzyme. 
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3.2 Introduction 
 
In mammals aspartate transcarbamoylase (ATCase) is a portion of a 
multifunctional enzyme (CAD)120 which is required for de novo pyrimidine nucleotide 
biosynthesis. The ATCase portion of CAD catalyses the second step in pyrimidine 
nucleotide biosynthesis, the reaction between carbamoyl phosphate and L-aspartate to 
give N-carbamoyl-L-aspartate and inorganic phosphate.121 ATCase has become a target 
for the development of anti-proliferative drugs and inhibitors of ATCase are considered 
as potential anti-tumor agents, since the levels of ATCase have been shown to be 
elevated in cancer cells.122 
 
N-(Phosphonoacetyl)-L-aspartate (PALA), a bi-substrate analogue of ATCase,37 
is a potent inhibitor which shows strong anti-proliferative90,123 and anti-tumor124,125 
activities in cell culture. It has been examined in clinical trials as a possible anti-
proliferation agent, however, a considerable drop in its effectiveness was observed.42 This 
is probably due to the difficult translocation of PALA in to cells,126 since the highly ionic 
nature of PALA makes it difficult for it to diffusion through the lipid bilayer of the cell 
membrane.127  
 
No structural data is available for CAD or the ATCase portion of CAD, however 
the amino acid sequences of the mammalian and E. coli enzymes are 43% identical, and 
therefore the structure of the E. coli enzyme has often been used as a model for the 
structure of the ATCase portion of CAD.85 All of the side chains important for catalytic 
activity in the E. coli enzyme are also present in the mammalian enzyme.  Finally, PALA 
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have been shown to be an effective inhibitor of both the mammalian and the E. coli 
enzymes.37,123 
 
Numerous analogues of PALA have been reported; unfortunately none of them 
are as potent as PALA.128-136 Functional group modifications of PALA, without 
significant perturbations to the core structure, may be a promising method to design new 
inhibitors for ATCase. Although several research groups have been interested in the 
chemical and biological consequences of the modification of the carboxyl groups in the 
aspartic acid portion of PALA by other functional groups like phosphonic48,137 or 
polyethyleneglycol monomethylether groups for a better prodrug,44 few studies have been 
performed to evaluate the effect of replacing the carboxylate moieties of PALA. This 
study describes the synthesis of a series of PALA analogues with modifications on the 
aspartate unit and determines how effective these compounds are in binding to and 
inhibiting the enzyme. Functional group modifications reported here include the 
introduction of alcohol and amide groups instead of the carboxylates at the α and β 
positions of the aspartate moiety, along with the replacement of the entire aspartate 
moiety with other amino acids such as aminomalonate, threonine, tyrosine and serine. In 
this communication, we report the design, synthesis, and inhibitory ability of this unique 
class of structurally modified PALA analogues (Figure 1), and describes aspects of their 
structure-activity relationship. 
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Figure 3.1. Structure of PALA and functional group modified analogues of PALA (1-9). 
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3.3 Results and Discussion 
 
 
A series of functional group modified PALA molecules (1-4) were synthesized 
according to Schemes 1-3. Initially, a hydroxy group was introduced in the α and/or β 
positions of the aspartate moiety and then an amide was introduced in both the α or β 
positions of the aspartate moiety.  
 
The β-hydroxy or homoserine derivative (2) was synthesized from commercially 
available β-benzyl-L-aspartate (10) in six steps (Figure 3.2). After protecting the α-
carboxylic acid as the t-butylester, chloroacetylation was performed on 11 to give the 
amide 12 in 68% yield. The reaction of chloroacetyl L-aspartate with triethyl phosphite 
under reflux conditions afforded the corresponding phosphonate ester (13) in good yield. 
Then the β-benzyl protecting group was removed using hydrogenolysis and the acid 
obtained (14) was further reduced to the alcohol (15) using NaBH4. The deprotection of t-
butyl and phosphonate esters of the alcohol provided the homoserine derivative of PALA 
(2).  
 
The bis hydroxy analog of PALA (4) was synthesized by a different synthetic 
route starting from diethyl L-aspartate (Figure 3.3). Reduction of ethyl ester of 16 using 
LiAlH4 gave the corresponding bis alcohol (17).138 After the sequential protection of the 
amino group as Boc and the hydroxy group as the benzyl ether, the Boc was cleaved with 
TFA and the resulting amine (23) was coupled with phosphonoacetic acid to afford the 
phosphonate ester (25) in 76% yield. Final deprotection of the phosphonate ester and 
benzyl ether under TMSBr conditions and hydrogenolysis, respectively afforded the bis 
hydroxy analog 4. 
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Figure 3.2.  Synthetic scheme for inhibitor 2: (a) H2SO4, isobutylene, dioxane, 20 h, 
74%; (b) chloroacetic anhydride (2 equiv), pyridine (5 equiv), CH2Cl2, 4 h, 68%; (c) 
P(OEt)3, 150 °C, 8 h, 97%; (d) 10% Pd/C, H2, EtOH, overnight, 92%; (e) (i) ethyl 
chloroformate (1.1 equiv), Et3N (1.1 equiv), -17 °C, 40 min, (ii) NaBH4 (3.5 equiv), 
THF/ H2O (4:1 v/v), 5 h, 59%; (f) TFA, CH2Cl2, 3 h; (g) (i) TMSBr (6 equiv), CH3CN, 0 
°C - rt, overnight, (ii) H2O, 1 h, 85%. 
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Figure 3.3.  Synthetic scheme for the synthesis of inhibitors 4 and 8: (a) LiAlH4 (3 
equiv), THF, 0 °C, then reflux for 30 min, 80% (b) di-tert-butyl dicarbonate (1.3 equiv), 
MeOH/t-BuOH (1:1, v/v), 24 h, 18 (92%); 19 (85%); (c) BnBr (3.7 equiv), KOH (3.7 
equiv), DMF, 4 h, 20 (59%); 21 (52%); (d) TFA, CH2Cl2, 3 h, 22 (83%); 23 (89%); (e) 
phosphonoacetic acid, Et3N (1 equiv), DCC (1.1 equiv), HOBt (1 equiv), CH2Cl2, THF, 
overnight, 24 (74%); 25 (76%); (f) (i) TMSBr (5.6 equiv), CH3CN, 0 °C - rt, overnight, 
(ii) H2O, 1 h, 98%; (g) 10% Pd/C, H2, EtOH, overnight, 8 (90%); 4 (77%). 
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The introduction of an amide group in the α or β positions resulted in significant 
changes in the ability of these compounds to inhibit ATCase. The synthesis and detailed 
studies of the α-amide derivative (1) has been reported139 and 1 showed nanomolar level 
inhibition of ATCase. The β-amide derivative (3) was synthesized by a shorter route from 
commercially available starting material, tert-butyl L-asparaginate (28) (Figure 3.4). 
Coupling of tert-butyl L-asparaginate with phosphonoacetic acid under standard amino 
acid coupling conditions afforded the phosphonate (30), which upon sequential 
deprotection of the t-butyl and the phosphonate esters resulted the β-amide analog (3) of 
PALA. 
 
All other structurally modified analogues were synthesized in 3 step reactions, 
except (8), using similar synthetic routes (Figure 3.5).129 The malonate alcohol derivative 
(8) was synthesized according to a similar method adopted for the synthesis of inhibitor 4 
(Scheme 3.3). 
 
Different protected amino acid or alcohol starting materials, either purchased 
(33a) or prepared (33 b-d), were reacted with phosphonoacetic acid to give the 
corresponding amino acid phosphonate derivatives (34 a-d). The phosphonate esters were 
first deprotected under TMSBr conditions, and then the alkyl esters were deprotected 
with LiOH to provide the derivatives (5-7, 9). 
 
 
 
 
 
 
 
 
   102 
 
 
 
 
 
 
 
 
NH2
NH2
O
O
+
HO
P
O O
OEt
OEt NH
NH2
O
O
O
P
O
OEt
OEt
tBuO
tBuO
NH
NH2
O
O
O
P
O
OEt
OEt
HO
NH
NH2
O
O
O
P
O
OH
OH
HO
28 29 30
a
b c
31 3  
 
 
 
Figure 3.4. Synthetic scheme for inhibitor 3: (a) Et3N (1 equiv), DCC (1.1 equiv), HOBt 
(1 equiv), CH2Cl2, THF, overnight, 85%; (b) 4 N HCl, dioxane, 0 °C - rt, 6 h, 100%; (c) 
(i) TMSBr (5.6 equiv), CH3CN, 0 °C - rt, overnight, (ii) H2O, 1 h, 81%. 
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Figure 3.5. Synthetic scheme for inhibitors 5 – 7 and 9: (a) SOCl2, CH3OH, 0 °C - rt, 
overnight, 33b (96%); 33c (92%); 33d (86%); (b) phosphonoacetic acid, Et3N (1 equiv), 
DIC (1.1 equiv), HOBt (1 equiv), CH2Cl2, THF, overnight, 34a (73%); 34b (38%); 34c 
(83%); 34d (73%); (c) (i) TMSBr (5.6 equiv), CH3CN, 0 °C - rt, overnight, (ii) H2O, rt, 1 
h, 35a (70%); 35b (93%); 35c (95%); 35d (90%); (d) LiOH, CH3OH, rt, 6 h, 5 (98%); 6 
(98%); 7 (95%); 9 (96%). 
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The ability of these compounds to inhibit ATCase (IC50) (1-9) was evaluated 
against the catalytic subunit of E. coli aspartate transcarbamoylase (ATCase) by a 
colorimetric determination of the amount of N-carbamoyl-L-aspartate formed.101 The 
results obtained are summarized in Table 1. These functional group modifications have a 
very large impact on the ability of these compounds to inhibit the enzyme. Compounds 1 
and 3 showed inhibition at the nanomolar level, which is very close to the inhibition 
observed for PALA.  Comparison of inhibitor 1 with PALA indicates that the amide 
modification in the α-position does not affect the inhibition significantly. Among the 
amide analogues, the α-amide showed more than two-fold better inhibition than the β-
amide, indicating that the β-carboxylate has more influence than the α-carboxylic group 
in the binding of the inhibitor. Though the analogues with an amide group did not make 
any dramatic changes in the observed inhibition as compared to PALA, introduction of 
the alcohol functionality resulted in analogues that were had substantially reduced ability 
to inhibit the enzyme. The mono alcohol 2 showed a 100-fold weaker inhibition 
compared to PALA, whereas the di-alcohol 4 only inhibited in the millimolar range.  All 
the structurally modified compounds, except 8 exhibited inhibition at the micromolar 
level. Inhibitor 5, which has one methylene unit less than PALA, showed an appoximate 
103-fold decrease in ability to inhibit the enzyme. A comparison of the IC50 values of 
inhibitors 5, 6 and 7 (see Table 1) indicates that the conversion of the carboxylate group 
into a primary or secondary alcohol does not have a significant influence on the 
inhibition, and also indicates that the relative position of the β-carboxylate moiety plays a 
crucial role in binding. 
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Table 3.1. IC50 values of inhibitors 1 - 9 and PALA against the catalytic 
subunit of ATCase 
 
 
 
R1
R2 NH
O
P
O
OH
OH
Compounds 1-4  
 
R3
NH
O
P
O
OH
OH
Compounds 5-9  
 
Compound R1 R2 R3 IC50  
(µM) 
PALA COOH COOH  0.055 
1 COOH CONH2  0.087 
2 CH2OH COOH  3.900 
3 CONH2 COOH  0.225 
4 CH2OH CH2OH  2900 
5   CH(COOH)2 43.50 
6   CH(COOH)CH2OH 30.00 
7   CH(COOH)CH(OH)CH3 42.00 
8   CH(CH2OH)2 12500 
9   CH(COOH)CH2-p(C6H4)OH 63.00 
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3.4 Conclusion 
 
 
In summary, we described the synthesis of a series of novel inhibitors for ATCase 
with a variety of structural modifications. Also studied was the effect of these 
modifications on the ability of these analogues to inhibit the activity in ATCase. These 
studies with functional group modified PALA derivatives showed that amide groups can 
be a useful substitute of the carboxylate group thereby reducing the charge on the 
molecule. IC50 values of these analogues indicated that the methylene unit in the β-
position is more critical than the functional group itself. Some of the newly synthesized 
molecules are potent inhibitors of ATCase and detailed functional and structural studies 
of these inhibitors with the enzyme are currently in process. 
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4.1 Abstract 
  
The identification of a proper lead compound for fructose 1,6-bisphosphatase 
(FBPase) is a critical step in the process of developing novel therapeutics against type-2 
diabetes.  Herein, we have successfully generated a library of allosteric inhibitors against 
FBPase as potential anti-diabetic drugs, of which, the lead compound 1b was identified 
through utilizing a virtual high-throughput screening (vHTS) system, which we have 
developed. . The thiazole-based core structure was synthesized via the condensation of α-
bromo-keotnes with thioureas and substituents on the two aryl rings were varied.  
Compound 4c was found to inhibit pig kidney FBPase approximately 5-fold better than 
1b.  In addition, we have also identified 10b, a tight binding fragment, which can be use 
for fragment-based drug design purposes. 
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4.2 Introduction 
 
In 2007, it was estimated that 7.8 percent of the population in the United States 
(23.6 million people) have diabetes,1 while the worldwide frequency of diabetes is 
expected to continue to grow by 6% annually, potentially reaching a total of 200 – 300 
million cases by 2010.2 In adults, type-2 diabetes, also known as non-insulin-dependent 
diabetes mellitus accounts for about 90 to 95 percent of all diagnosed cases of diabetes. 
The liver has a critical role in regulating endogenous glucose production from de novo 
synthesis (gluconeogenesis) or the catabolism of glycogen (glycogenolysis).3,4 Increased 
rates of hepatic glucose production are largely responsible for the development of overt 
hyperglycemia, in particular fasting hyperglycemia, in patients with diabetes.4 Therefore 
enzymes that regulate rate-controlling steps in the gluconeogenic or glycogenolytic 
pathways are obvious molecular targets for therapeutic interventions.5 As a rate-limiting 
and highly regulated enzyme in the gluconeogenesis pathway, fructose-1,6-
bisphosphatase (FBPase) is an attractive target in the development of new anti-diabetic 
pharmaceuticals. 
 
FBPase is a tetramer of four identical polypeptide chains (Mr 34,000/chain) and 
exists as a dimer of dimers.6 The enzyme exists in at least two distinct quaternary 
conformations called R and T.7,8 The enzyme is subject to competitive substrate 
inhibition by fructose-2,6-bisphosphate9 and to allosteric inhibition by adenosine 
monophosphate (AMP). A “novel allosteric site” has also been identified at the center of 
the molecule where the four subunits converge.9,10 The enzyme does not exhibit substrate 
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cooperativity but is cooperative with respect to the binding of AMP and metal 
cofactors.10 Without effectors the enzyme exists in the R-quaternary structure. AMP 
induces the transition from the active R-state to the inactive T-state.11 
 
Targeting the AMP binding site has historically been challenging due to the 
abundance of AMP-binding enzymes controlling other key biosynthetic pathways 
resulting in issues with specificity.  Other difficulties that need to be overcome include 
the hydrophilic nature of AMP sites and their reliance on the negatively charged 
phosphate group of AMP for binding affinity.12 Target-based virtual database screening 
has become a useful tool for the identification of inhibitors for protein-ligand and protein-
protein interactions.13 In light of the abovementioned challenges, virtual screening, in the 
use of high-performance computing to analyze chemical databases and prioritize 
compounds for synthesis and assay,14 then provides a more cost-effective approach to 
discovering allosteric inhibitors that bind to the desired allosteric site and yet are 
structurally distinct from the traditional AMP analogs.    
 
In the present work, we have successfully generated a library of allosteric 
inhibitors against FBPase of which, the lead compound was identified utilizing virtual 
high-throughput screening (vHTS) system, which we have developed.  In this paper, the 
synthesis and the ability of the compounds in this library to inhibit FBPase in vitro are 
also described, thus demonstrating how vHTS can be utilized to find and develop novel 
inhibitors against FBPase.       
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4.3 Results 
 
In Silico Screening 
The identification of a proper lead compound for FBPase is a critical step in the 
process of developing novel therapeutics against diabetes. To this end, target-based 
virtual database screening has become a useful tool for the identification of inhibitors for 
protein-ligand and protein-protein interactions.15,16 In our laboratory, we have in-place, a 
vHTS system that is set-up to screen millions of compounds against a desired target. The 
two essential components for a successful screen are the docking software and the 
database of small molecules.  In an effort to make virtual screening more accessible to a 
broader community, Irwin et al.15 developed ZINC, a free database of structures of small 
molecules, many of them “drug-like” or “lead-like”.  Virtual screening using the ZINC 
database have now been used for the development of inhibitors for a variety of targets 
including cyclooxygenase-2,16 anthrax edema factor17 and the H5N1 avian influenza 
virus.18  
 
The virtual high-throughput screening system we have developed consists of four 
parts: (1) a MySQL database containing entries of the molecules in the ZINC6 database 
in mol2, pdbq and mae format, (2) a set of unix tar files containing the executable 
program and associated auxiliary files for AUTODOCK,19 SUFLEX20 DOCK5,21 and 
GLIDE24,25 (Schrödinger, Inc.), (3) a MySQL database for storage of the results of the 
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docking calculations, and (4) a UNIX shell script that automates the process and provides 
the ability to distribute the computations over multiple computers.  
 
Validation of AUTODOCK and DOCK5 were performed utilizing the structure of 
human FBPase with AMP bound (PDB entry 1FTA).  AMP was first removed from its 
site, and its coordinates changed so that AMP was in a different spatial position, distant 
from the actual binding site. AMP was then docked into the allosteric site of human 
FBPase using the respective docking programs.  Both programs performed well in 
matching the docked conformation with the one observed in the crystal structure.  
 
We then screened the ~3 million compounds that are characterized as purchasable 
in the ZINC6 database, against the AMP-binding site of human FBPase.  Compounds 
were ranked based on the most favorable interaction energy of each ligand against the 
protein. The eventual selection of the compounds for in vitro biochemical assay were 
based on the following criteria: (1) actual commercial availability, (2) maximizing 
chemical diversity, and (3) on the basis of whether the compounds were drug-like as 
defined by Lipinski’s rule of 5.22 
 
Experimental Assays 
The selected compounds were assayed for inhibitory activity using purified pig 
kidney FBPase, employing a coupled-enzyme assay with AMP as the control.23 The 
degree of amino acid sequence conservation within the FBPase coding region among 
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mammalian species is very high, with 90% of the residues identical and another 6% 
similar. Thus the pig kidney enzyme is an excellent model system to study enzyme 
inhibition with respect to human FBPase. In addition, the use of pig kidney enzyme was 
conducted to support our ongoing crystallographic work using this enzyme. Figure 1 
illustrates some of the compounds from this screen that were found to inhibit pig kidney 
FBPase.  As shown, the vHTS system successfully identified inhibitors of pig kidney 
FBPase with a broad spectrum of inhibitory activities, ranging from 10 mM to 20 µM.  
Of these, we decided to pursue a more detailed structure activity relationship (SAR) study 
of 1.  Compound 1, contains a thiazole ring, a functionality that have been found to be 
associated with a plethora of biological activities,28 several of which have been developed 
into potent inhibitors of FBPase.9,29 More importantly, 1 was chosen because it has 
reasonable activity (IC50 of 31.6 ± 1.6 µM) and possesses two aromatic rings that would 
allow for a variety of functional groups to be investigated.  
 
Chemistry 
The synthesis of the inhibitors shown in Table 1 was carried out by modifying 
reported procedures and is illustrated in Figure 1.  Where the primary thiourea could not 
be purchased commercially, it was easily synthesized by reacting the respective amine 20 
– 24 with excess potassium thiocynate in the presence of one equivalent concentrated 
HCl. In most cases, the pure primary thioureas could be isolated by precipitation and 
purified in good yield by crystallization.24 The condensation of α-halogeno ketones 25 – 
28 with the N-monosubstituted thioureas 11 – 15 via the Hantzsch reaction were 
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originally accomplished by heating the reaction mixture under reflux, with varying 
reaction times from 7 h to 24 h.28,31 Although combinatorial chemistry has been widely 
adopted in drug discovery in recent years, it can be both labor and time intensive. 
Generating a small library of 29 compounds via a two-step synthetic pathway as 
described, would require setting up to 29 reaction vessels, each used twice. This was 
made more challenging when problems arose in the second synthetic step.  Even after 24 
hrs, overall yields were low (< 30%) and purifications were tedious.   
 
In order to enhance the capabilities of combinatorial chemistry, we modified the 
second synthetic step according to the recent work by Kabalka and Mereddy,25 who 
demonstrated the use of microwave irradiation to promote the rapid one-pot synthesis of 
a series of 2-aminothiazoles. Using the same methodology, we were able to reduced the 
reaction times from 24 h to a mere 45 sec and increased the yields from less than 30% to 
greater than 90% after recrystallization.  
 
Having designed an efficient route to the compounds in groups 1 - 8, we were 
able to expand the library further by synthesizing the 2-aminothiazole fragments 
according to Figure 2.   Compounds 10a – 10c (Table 2), were synthesized from thiourea 
19 via microwave irradiation according to the method described above. 
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Figure 4.1. Structures and IC50 of AMP and various inhibitors identified by the vHTS 
system. 
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Figure 4.2. Synthetic scheme for inhibitors 1a – 8e: (i) conc. HCl, potassium thiocynate, 
EtOH, reflux, 18 h (ii) EtOH, MW, 45 sec. 
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Figure 4.3. Synthetic scheme for inhibitors 10a-10c: (i) EtOH, MW, 45 sec. 
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4.4 Discussion 
 
The ability of compounds 1 – 29 to inhibit the activity of pig kidney FBPase was 
determined using a coupled-enzyme assay23 with AMP as the control, and the results 
obtained are showed in Tables 1 and 2. To validate our results, all 29 inhibitors were 
docked against the allosteric site of a pig kidney T-state crystal structure (PDB entry 
1FRP) using the high precision mode (XP) mode in Glide (SchrÖdinger).26 A graph of 
IC50 values was plot against the resultant docking score obtained from Glide.  As showed 
in Figure 4.3, there is good agreement between the actual inhibitory activity against the 
pig kidney enzyme and the binding affinity as predicted by Glide.    
 
The results displayed in Tables 1 and 2 revealed that substituting a hydroxyl at R5 is 
essential for inhibition.  This trend is consistent regardless of the substitution on ring 1, as 
inhibitors with hydroxyl functionality at R5 resulted in improved inhibition over those 
without.  Remarkably, while 7a, even at 300 µM, showed no significant inhibitory 
activity against the enzyme, the R5 hydroxyl substituted 7b inhibited the enzyme at an 
IC50 of 48 ± 3 µM. Likewise, a comparison of 5a (IC50 = 270 ± 14 µM) with 5b (IC50 = 
15 ± 1 µM) showed that the R5 hydroxyl substitution (5b) resulted in an ~18-fold 
improved inhibition.  On the other hand, functionalizing R5 with nitro instead of 
hydroxyl, eliminated inhibition.  For example, a comparison of 3a (IC50 = 124 ± 6 µM) 
with 3b (IC50 = 48 ± 3 µM) and 3d showed that the inhibitory activity of the inhibitor 
with an R5 hydroxyl substitution (3b) improved 3-fold from 3a while having its 
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inhibitory activity eliminated when the hydroxyl is replaced by nitro at R5 (3d). 
Similarly, a nitro group at R5 in 8e eliminates inhibition compared to 8a (IC50 = 2.5 ± 0.1 
mM) and 8b (IC50 = 320 ± 4 µM). 
 
 
Table 4.1. Inactivation of pig kidney FBPase by inhibitors 1a – 9b. 
 
 
Ring 1         Ring 3 
S
NN
H R4
R5
R1
R2
R3
1a - 9b  
Compound R1 R2 R3 R4 R5 FBPase, IC50 (µM) 
1a H H SO2NH2 H H 145 ± 11 
1b H H SO2NH2 H OH 32 ± 2 
1c H H SO2NH2 OH OH 55 ± 0.5 
2a H SO2NH2 H H H 104 ± 7 
2b H SO2NH2 H H OH 50 ± 6 
3a H H OH H H 124 ± 6.0 
3b H H OH H OH 48 ± 3.0 
3c H H OH OH OH 11 ± 0.5 
3d H H OH H NO2 NDa 
4a H OH H H H 35 ± 4 
4b H OH H H OH 13 ± 0.5 
4c H OH H OH OH 6 ± 0.5 
5a OH H H H H 270 ± 14 
5b OH H H H OH 15 ± 1 
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5c OH H H OH OH 20 ± 2 
6a H H NO2 H H NDb 
6b H H NO2 H OH 246 ± 12 
7a H NO2 H H H NDb 
7b H NO2 H H OH 48 ± 3 
8a H H H H H 2500 ± 110 
8b H H H H OH 318 ± 4 
8c H H H OH OH 343 ± 4 
8d H H H OH H 119 ± 4 
8e H H H H NO2 NDb 
9ac H COOH H H H 571 ± 5.0 
9bc H COOH H H OH 48 ± 4 
a Approximately 87 % inhibition at 100 µM. 
b No detectable inhibition observed. 
c Commercially available compounds. 
 
 
Table 4.2. Inactivation of pig kidney FPBase by inhibitors 10a – 10c. 
 
H2N S
N
R5
R4
10a -10c  
 
Compounds R4 R5 FBPase, IC50 (µM) 
10a H H 1392 ± 68 
10b H OH 1.1 ± 0.1 
10c OH OH 93 ± 5 
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Figure 4.4. Graph of IC50s from 1a – 10c against the resultant docking score obtained 
from the high-precision mode (XP) from Glide.26 A more negative docking score 
represents tighter binding and therefore predicts better inhibition. Kaleidagraph was used 
to plot the graph with two outlaying points removed (3d and 10b). 
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Given the high concentration of positively charged resides present at the AMP 
binding site as shown in Figure 5.4, it is reasonable to assume that by adding a second 
hydroxyl at R4, that the binding affinity of the inhibitors for the allosteric site might 
increase.  This is true for groups 3 and 4 where the additional hydroxyl at R4 improved 
enzyme inhibition. However, with the rest, the differences in inhibitory activity between 
the single and double hydroxyls were negligible. 
 
Manipulation of the substituent positions on Ring 1 within the same functional 
group seemed to have little effect on activity.  This is demonstrated by the relative small 
changes in inhibitory activity between 1a (IC50 = 145 ± 11 µM) and 2a (IC50 = 104 ± 7 
µM) where the sulfonamide was moved from R3 to R2. Similar observations can be made 
for the hydroxyl and nitro substitutions at R1, R2 an R3. Given the relative size differences 
between these functional groups, this may suggest that the area where Ring 1 binds is not 
restrictive.  However, between the different functional groups, there is a marked effect on 
the activity of the inhibitor.  Overall, it would seem that hydroxyls are better for activity 
as opposed to sulfonamides and nitros.  Inhibitors with no substitution on Ring 1 seemed 
to fare the worst as a group. 
 
In order to confirm that the FBPase inhibition by the achyrofuran analogs was due 
to binding at the allosteric site and not the active site, a competition experiment was 
performed using the analog of AMP, 2’,3’-O-(2,4,6-trinitrophenyl)adenosine 5-
monophosphate (TNP-AMP). This analog has been shown to bind at the allosteric site of 
   127 
FBPase and exhibits fluorescence only when bound to the enzyme.  TNP-AMP was 
added to the FBPases at a concentration equal to 0.5 times their respective Kd. Increasing 
concentrations of the respective inhibitors were added which resulted in a substantial 
diminution of the TNP-AMP fluorescence, indicating that these inhibitors may be 
competing with TNP-AMP at the allosteric site. Binding constants for the inhibitors 
could not be determined by this method due to the relatively low solubility of these 
compounds. 
 
In an effort to develop potent inhibitors against FBPase, part of our strategy is to 
use the fragment based approach to enhance inhibitor affinity. Thus, we investigated the 
effect that the phenylthiazole fragment 10a – 10c have on the enzyme activity.  To our 
surprise, the fragment 4-(2-aminothiazol-5-yl)phenol 10b, inhibited the enzyme with an 
IC50 of 1.1 ± 0.1 µM, having better inhibitory activity than all the diphenylthiazole-based 
inhibitors found in Table 1.  In addition, the binding of 10b at the allosteric site was 
observed in a low resolution X-ray crystallography data of the enzyme•10b complex that 
we had obtained.  
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Figure 4.5. X-ray crystal structure of AMP bound to pig kidney FBPase at the allosteric 
site. (PDB entry 1RDZ). The electrostatic potentials calculated using the Adaptive 
Poisson-Boltzmann Solver27 were map on a surface representation of the protein created 
using PyMol. 
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4.5 Conclusion 
 
Compounds 1a – 9b represent a novel class of inhibitors against FBPase that are 
not analogs of AMP.  The in vitro data in Table 1 and the observation of inhibitor 
electron density in a low-resolution structure of pig kidney FBPase•1b demonstrated how 
a vHTS system was used to identify and develop novel inhibitors against FBPase.  By 
substituting the sulfonamide on the original molecule (1b) as identified by the vHTS 
system , and adding a hydroxyl at R2 to ring 1 and a second hydroxyl at R4 to ring 3, we 
have designed and synthesized 4c (IC50 = 6 ± 0.5 µM) which has a 5-fold increased in 
potency over 1b (IC50 = 32 ± 2 µM) against pig kidney FBPase. Currently, one of the 
most potent allosteric inhibitor of FBPase is MB05032, which inhibits human liver 
FBPase at an EC50 of 16 nM, a value that is approximately 370-fold better than 4c.  
However, in line with the fragment-based drug design strategy, a future goal is to obtain 
higher resolution X-ray data of the enzyme•10b complex so that we can use the resultant 
structure, with 10b bound, in our vHTS system to screen for fragments that have a high 
(micromolar or better) affinity for the allosteric site.  Thus, by synthetically linking the 
appropriate fragment with 10b, we will be able to generate a more potent and specific 
inhibitor of FBPase.    
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4.6 Experimental 
 
Isolation and purification of Pig kidney FBPase 
Plasmid pEK28428 was transformed into Escherichia coli strain EK1601.29 
Bacteria were cultured with vigorous agitation at 37 °C in YT30 media containing 
ampicillin at 100 µg per mL.  Induction of T7 RNA polymerase was initiated by addition 
of 0.4 mM isopropyl-ß-D-thiogalactopyranoside.  After further growth for 16 - 22 h, the 
cells were harvested by centrifugation, broken open by sonication, and purified as 
described previously29 with the modification of eluting from the Dyematrex Blue A 
column with a 50 mM KH2PO4 buffer at pH 7.5 containing 5 mM ATP instead of AMP.  
Pure fractions were pooled and dialyzed extensively against a buffer containing 50 mM 
KH2PO4 and 1 mM MgCl2 at pH 7.5 before performing enzyme activity assays.   
 
Measurement of FBPase Activity 
FBPase activity was measured spectrophotometrically by employing the coupling 
enzymes phosphoglucose isomerase and glucose-6-phosphate dehydrogenase.23 The 
reduction of NADP+ to NADPH was monitored directly at 340 nm. Specifically, buffer 
(0.2 M Tris, 4 mM MgCl2, 4 mM (NH4)2SO4, 0.1 EDTA, pH 7.5), 0.2 mM of NADP+, 1.4 
units of phosphoglucose isomerase and 0.5 units glucose-6-phosphate dehydrogenase, 0 – 
300 µM of inhibitor and 9 ng of FBPase, were mixed in a cuvette and equilibrated at 30 
°C. 70 µM of FBP was then added to initiate the reaction. A340 data were collected as a 
function of time using a JASCO V-630 spectrophotometer. After a lag phase, due to 
coupling, a straight line was fit to the progress curve and the slope was determined as 
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ΔA340 per min. The amount of NADPH produced per min. was calculated using the 340 
nm millimolar extinction coefficient of 6.22. At each inhibitor concentration, reactions 
were performed in duplicate. Inhibition curves were obtained for each compound by 
plotting the relative activity versus inhibitor concentration. 
 
Fluorescence Measurements 
Fluorescence data were collected using a JASCO FP-6300 spectrofluorometer. 
Excitation and emission wavelengths of 410 and 535 nm respectively were used for TNP-
AMP (Molecular Probes). 0.15 mg of the respective FBPases, 0.08 mM MgCl2 and 20 
µM fructose 1,6-bisphosphate in 50 mM Tris-acetate buffer, pH 7.5, was added to a 2 mL 
cuvette and stirred. 3.5 µM of TNP-AMP was added to the cuvette and the emission data 
was obtained. Microliter volumes of each inhibitor were subsequently added to the 
cuvette and resultant emission data was obtained after each addition. The final 
concentration of each inhibitor in the enzyme solution was between 5 to 50 µM.  
 
Chemistry  
All materials were reagent grade and used without further purification. Thin-layer 
chromatography (TLC) was performed on silica gel 60 aluminum backed pates (250 
microns) from Sorbent Technologies and visualized by Abs254 irradiation. Flash 
chromatography was conducted with silica gel 60 (230 mesh) from AK Scientific Inc. All 
final products were characterized by 1H NMR and HRMS.  Purity of all final compounds 
were determined by HPLC. 1H NMR spectra were recorded on a Varian 400 
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spectrometer. Proton chemical shifts are reported in ppm (δ) relative to internal 
tetramethylsilane (TMS, δ 0.0) or with the solvent reference relative to TMS employed as 
the internal standard (CDCl3, δ 7.24 ppm; DMSO-d6, δ 2.50). Standard abbreviations 
indicating multiplicity were used as follows: s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet and br = broad.  Mass spectra were obtained at the Mass 
Spectrometry Facilities at Boston College. HPLC separations were performed on a 
Biologic Duo-Flow chromatrography system (BioRad). Microwave reactions were 
performed using a General Electric Spacemaker II, operating at 400W. 
 
 
Preparation of analogs 
5.3.2.1. 4-Thioureidobenzenesulfonamide (11). A solution of sulfanilamide 20 
(3g, 0.017 mol) in 15 mL of ethanol was stirred at room temperature while concentrated 
hydrochloric acid (37.4%, 2.14 mL) was added dropwise.  The suspension that formed 
was heated to reflux and when all suspension had dissolved, a solution of potassium 
thiocynate (2.6 g, 0.0255 mol) in 5 mL of ethanol was added to the suspension.  The 
reaction mixture was stirred at reflux for 18 h.  The precipitate formed upon cooling was 
dried under vacuum and recrystallized from ethanol to yield 3g (76.3%) of 11 as white 
solid; 1H (DMSO-d6): 7.28 (br, 2H), 7.70-7.75 (m, 4H), 10.21 (br, 1H). 
 
4-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)benzenesulfonamide (1b). A solution 
of 11 (200 mg, 0.86 mmol) and 2-bromo-4’-hydroxyacetophenone 25 (188mg, 0.87 
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mmol) in 5 mL of ethanol were placed in the microwave cavity and subjected to MW 
irradiation at 71 °C (400 W) for 45 sec.  The reaction mixture was cooled to room 
temperature and solvent was removed under vacuo.  The resultant solid was washed with 
ethanol and crystallized from ethanol / n-pentane to yield 280 mg (94%) of 1b as a pale 
yellow solid; 1H (DMSO-d6): 6.73 (d, J = 8.8 Hz, 2H), 7.07 (s, 1H), 7.65-7.70 (m, 4H), 
7.78 (d, J = 8.8 Hz, 2H,), 10.57 (br, 1H). HRMS (ESI) [M + H]+ calcd for C15H14N3O3S2, 
348.0477; found 348.0486. 
 
4-(4-Phenylthiazol-2-ylamino)benzenesulfonamide (1a) (275 mg, 97%, white 
solid) was prepared in a similar manner as described for the synthesis of 1b except using 
2-bromoacetophenone 26. (DMSO-d6): 7.21 (br, 2H), 7.34 (m, 1H), 7.45 (d, J = 9.6 Hz, 
2H), 7.46 (s, 1H), 7.80-7.90 (m, 4H), 7.96 (d, J = 8.0 Hz, 2H), 10.74 (bs, 1H). HRMS 
(ESI) [M + H]+ calcd for C15H14N3O2S2, 332.0527; found 332.0522. 
 
4-(4-(2,4-Dihydroxyphenyl)thiazol-2-ylamino)benzenesulfonamide (1c) (300 mg, 
96%, brown solid) was prepared in a similar manner as described for the synthesis of 1b 
except using 2-bromo-2’-4’-dihydroxyoacetophenone 27. 1H (DMSO-d6): 6.36 (d, J = 8.8 
Hz, 1H), 6.40 (br, 1H), 7.27 (s, 1H), 7.74-7.82 (m, 5H), 10.84 (br, 1H). HRMS (ESI) [M 
+ H]+ calcd for C15H14N3O2S2, 332.0527; found 332.0517. HRMS (ESI) [M + H]+ calcd 
for C15H14N3O4S2, 364.0426; found 364.0443. 
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3-Thioureidobenzenesulfonamide (12) (800 mg, 60%, white solid) was prepared 
in a similar manner as described for the synthesis of 11 and by substituting sulfanilamide 
with 3-aminobenzenesulfonamide 21. 1H (DMSO-d6): 7.37 (s, 1H), 7.48-7.56 
(overlapped, m, 2H), 7.70 (d, J = 7.6 Hz, 1H), 7.93 (bs, 2H), 9.95 (br, 2H) 
 
3-(4-Phenylthiazol-2-ylamino)benzenesulfonamide (2a) (560 mg, 90%, yellow 
solid) was prepared from 12 and according to the manner described for 1a. 1H (DMSO-
d6): 6.82 (d, J = 8.8 Hz, 2H), 7.17 (s, 1H), 7.18 (d, J = 9.6 Hz, 1H), 7.76 (d, J = 8.8 Hz, 
2H), 7.78 (d, J = 7.6 Hz, 2H), 7.85 (s, 1H), 7.86 (d, J = 9.2 Hz, 1H), 9.58 (s, 1H), 10.5 (s, 
1H). HRMS (ESI) [M + H]+ calcd for C15H14N3O2S2, 332.0527; found 332.0517. 
 
3-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)benzenesulfonamide (2b) (600 mg, 
93%, brown solid) was prepared from 12 and according to the manner described for 1b. 
1H (DMSO-d6): 6.52 (s, 1H), 6.78-6.86 (overlapped, m, 4H), 7.47 (d, J = 7.2 Hz, 2H), 
7.80 (d, J = 7.6 Hz, 2H), 9.80 (br, 1H), 10.40 (br, 1H), 11.61 (br, 1H). HRMS (ESI) [M + 
H]+ calcd for C15H14N3O3S2, 348.0477; found 348.0492.  
 
4-(4-Phenylthiazol-2-ylamino)phenol (3a) (158 mg, 93%, white solid) was 
prepared from commercially available 1-(4-hydroxyphenyl)thiourea 13 and according to 
the manner described for 1a. 1H (DMSO-d6): 6.76 (d, J = 8.8 Hz, 2H), 7.23 (s, 1H), 7.30 
(t, J = 7.4 Hz, 1H), 7.42 (t, J = 7.4 Hz, 2H), 7.48 (d, J = 6.8 Hz, 2H), 7.89 (d, J = 7.2 Hz, 
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2H), 9.95 (br, 1H). HRMS (ESI) [M + H]+ calcd for C15H13N2OS, 269.0749; found 
269.0740. 
 
4-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol (3b) (154 mg, 91%, white 
solid) was prepared from 13 and according to the manner described for 1b. 1H (DMSO-
d6): 6.76 (d, J = 8.8 Hz, 2H), 6.80 (d, J = 8.8 Hz, 2H), 6.95 (s, 1H), 7.44 (d, J = 8.8 Hz, 
2H), 7.68 (d, J = 8.8 Hz, 2H), 9.97 (br, 1H). HRMS (ESI) [M + H]+ calcd for 
C15H13N2O2S, 285.0698; found 285.0698. 
 
4-(2-(4-Hydroxyphenylamino)thiazol-4-yl)benzene-1,3-diol (3c) (40 mg, 94 %, 
brown solid) was prepared from 13 and according to the manner described for 1c. 1H 
(DMSO-d6): 6.31 (d, J = 8.4 Hz, 1H), 6.32 (s, 1H), 6.81 (d, J = 8.8 Hz, 2H), 7.01 (s, 1H), 
7.27 (d, J = 8.8 Hz, 2H), 7.53 (d, J = 8.0 Hz, 1H), 10.29 (br, 1H). HRMS (ESI) [M + H]+ 
calcd for C15H13N2O3S, 301.0647; found 301.0652. 
 
4-(4-(4-Nitrophenyl)thiazol-2-ylamino)phenol (3d) (176 mg, 95%, yellow solid) 
was prepared from 13 and according to the manner described for 1b except using 2-
Bromo-4’-nitroacetophenone. 1H (DMSO-d6): 6.77 (d, J = 8.8 Hz, 2H), 7.48 (d, J = 8.8 
Hz, 2H), 7.63 (s, 1H), 8.15 (d, J = 9.2 Hz, 2H), 8.29 (d, J = 9.2 Hz, 2H) 10.06 (br, 1H). 
HRMS (ESI) [M + H]+ calcd for C15H12N3O3S, 314.0599; found 314.0612. 
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1-(3-Hydroxyphenyl)thiourea (14) (480 mg, 44%, white solid) was prepared in a 
similar manner as described for the synthesis of 11 and by substituting sulfanilamide with 
3-Aminophenol 22. 1H (DMSO-d6): 6.52 (d. J = 8.2 Hz, 1H), 6.85 (d, J = 8.6 Hz, 1H), 
7.00 (s, 1H), 7.10 (t, J = 8.0 Hz, 1H), 9.44 (s, 1H), 9.65 (s, 1H), 9.64 (s, 1H)  
 
3-(4-Phenylthiazol-2-ylamino)phenol (4a) (290 mg, 91%, white solid) was 
prepared from 14 and according to the manner described for 1a. 1H (DMSO-d6): 6.50 (d, 
J = 8.4 Hz, 1H), 6.71 (s, 1H), 6.74-6.77 (m, 2H), 7.08 (t, J = 8.0 Hz, 1H), 7.24-7.28 (m, 
1H), 7.34 (t, J = 7.6 Hz, 2H), 7.77 (d, J = 8.0 Hz, 2H). HRMS (ESI) [M + H]+ calcd for 
C15H13N2OS, 269.0749; found 269.0748. 
 
3-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol (4b) (305 mg, 96%, pale green 
solid) was prepared from 14 and according to the manner described for 1b. 1H (DMSO-
d6): 6.37 (dd, J = 7.4, 1.8 Hz, 1H), 6.81 (d, J = 8.8 Hz, 2H), 7.01 (d, J = 8.4 Hz, 1H), 7.04 
(s, 1H), 7.09 (t, J = 8.0 Hz, 1H), 7.31 (t, J = 2.2 Hz, 1H), 7.75 (d, J = 8.3 Hz, 2H), 10.09 
(br, 1H). HRMS (ESI) [M + H]+ calcd for C15H13N2O2S, 285.0698; found 285.0700. 
 
4-(2-(3-Hydroxyphenylamino)thiazol-4-yl)benzene-1,3-diol (4c) (322 mg, 90%, 
brown solid) was prepared from 14 and according to the manner described for 1c. 1H 
(DMSO-d6): 6.30-6.32 (overlapped, m, 2H), 6.42 (dd, J = 8.0, 2.4 Hz, 1H), 6.92-6.90 (m, 
1H), 7.01 (t, J = 2.0 Hz, 1H), 7.126 (s, 1H), 7.126 (t, J = 8.0 Hz, 1H), 7.68 (d, J = 9.2 Hz, 
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1H), 10.25 (bs, 1H). HRMS (ESI) [M + H]+ calcd for C15H13N2O3S, 301.0647; found 
301.0656. 
 
1-(2-Hydroxyphenyl)thiourea (15) (720 mg, 47%, white solid) was prepared in a 
similar manner as described for the synthesis of 11 and by substituting sulfanilamide with 
2-aminophenol 23.  1H (DMSO-d6): 6.76 (t, J = 7.2 Hz, 1H), 6.86 (d, J = 8.0 Hz, 1H), 
6.93-6.99 (m, 2H), 7.76 (br, 1H), 8.92 (br, 1H), 9.75 (br, 1H). 
 
2-(4-Phenylthiazol-2-ylamino)phenol (5a) (293 mg, 92%, white solid) was 
prepared from 15 and according to the manner described for 1a. 1H (DMSO-d6): 6.37-
6.40 (m, 1H), 6.82 (d, J = 8.8 Hz, 2H), 7.00-7.02 (m, 1H), 7.04 (s, 1H), 7.10 (t, J = 8 Hz, 
1H), 7.31 (t, J = 2.2 Hz, 2H), 7.74 (d, J = 8.8 Hz, 2H), 10.13 (br, 1H). HRMS (ESI) [M + 
H]+ calcd for C15H13N2OS, 269.0749; found 269.0751.  
 
2-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol (5b) (300 mg, 94%, white 
solid) was prepared from 15 and according to the manner described for 1b. 1H (DMSO-
d6): 6.37-6.39 (m, 1H), 6.82 (d, J = 8.8 Hz, 2H), 7.00-7.02 (m, 1H), 7.11 (t, J = 8 Hz, 
1H), 7.30 (t, J = 2.2 Hz, 2H), 7.74 (d, J = 8.8 Hz, 2H), 10.13 (br, 1H). HRMS (ESI) [M + 
H]+ calcd for C15H13N2O2S, 285.0698; found 285.0704. 
 
4-(2-(2-Hydroxyphenylamino)thiazol-4-yl)benzene-1,3-diol (5c) (330 mg, 92%, 
dark brown solid) was prepared from 15 and according to the manner described for 1c. 1H 
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(DMSO-d6): 6.30 (d, J = 2.4 Hz, 1H), 6.32 (br, 1H), 6.86 (t, J = 7.3 Hz, 1H), 6.93-7.00 
(m, 2H), 7.05 (s, 1H), 7.53 (d, J = 9.0 Hz, 1H), 7.65 (d, J = 7.8 Hz, 1H), 9.93 (br, 1H). 
HRMS (ESI) [M + H]+ calcd for C15H13N2O3S, 301.0647; found 301.0634. 
 
N-(4-Nitrophenyl)-4-phenylthiazol-2-amine (6a) (700 mg, 93 %, orange solid) 
was prepared from commercially available 1-(4-nitrophenyl)-2-thiourea 16, according to 
the manner described for 1a. 1H (DMSO-d6): 7.35 (t, J = 6.6 Hz, 1H), 7.46 (t, J = 7.8 Hz, 
2H), 7.57 (s, 1H), 7.85 (d, J = 9.2 Hz, 2H), 8.19 (d, J = 11.6 Hz, 2H), 8.28 (d, J = 9.2 Hz, 
2H), 10.29 (br, 1H). HRMS (ESI) [M + H]+ calcd for C15H12N3O2S, 298.0650; found 
298.0650.   
 
4-(2-(4-Nitrophenylamino)thiazol-4-yl)phenol (6b) (755 mg, 95%, orange solid) 
was prepared from 16 and according to the manner described for 1b. 1H (DMSO-d6): 6.83 
(d, J = 8.8 Hz, 2H), 7.28 (s, 1H), 7.79 (d, J = 8.4 Hz, 2H), 7.94 (d, J = 9.2 Hz, 2H), 8.27 
(d, J = 9.6 Hz, 2H), 11.05 (br, 1H). HRMS (ESI) [M + H]+ calcd for C15H12N3O3S, 
314.0599; found 314.0600. 
 
1-(3-Nitrophenyl)thiourea (17) (742 mg, 52%, yellow solid) was prepared in a 
similar manner as described for the synthesis of 11 and by substituting sulfanilamide with 
3-nitroaniline 24. 1H (DMSO-d6): 7.60 (t, J = 8.0 Hz, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.94 
(d, J = 8.4 Hz, 1H), 8.62 (s, 1H), 10.11 (br, NH) 
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N-(3-Nitrophenyl)-4-phenylthiazol-2-amine (7a) (286 mg, 95%, orange solid) was 
prepared from 17 and according to the method described for 1a. 1H (DMSO-d6): 7.20-
7.30 (m, 4H), 7.42 (dd, J = 0.8, 8.0 Hz, 1H), 7.60-7.67 (m, 2H), 7.76 (dd, J = 7.8, 8.0 Hz, 
1H), 7.82 (t, J = 2.0 Hz, 1H), 7.89 (dd, J = 8.2, 1.0 Hz, 1H), 10.3 (br, 1H). HRMS (ESI) 
[M + H]+ calcd for C15H12N3O2S, 298.0650; found 298.0650. 
 
4-(2-(3-Nitrophenylamino)thiazol-4-yl)phenol (7b) (302 mg, 95%, yellow solid) 
was prepared from 17 and according to the method described for 1b. 1H (DMSO-d6): 6.84 
(d, J = 8.4 Hz, 2H), 7.20 (s, 1H), 7.62 (t, J = 8.2 Hz, 1H), 7.79-7.82 (m, 3H), 7.95 (d, J = 
8.0 Hz, 1H), 9.01 (t, J = 2.4 Hz, 1H), 9.62 (s, 1H), 10.78 (br, 1H). HRMS (ESI) [M + H]+ 
calcd for C15H12N3O3S, 314.0599; found 314.0606. 
 
N,4-Diphenylthiazol-2-amine (8a) (763 mg, 92%, yellow solid) was prepared 
from commercially available phenylthiourea 18 and according to the method described 
for 1a. 1H (DMSO-d6): 6.99 (t, J = 7.4 Hz, 1H), 7.31-7.39 (m, 4H), 7.45 (t, J = 7.6 Hz, 
2H), 7.76 (d, J = 7.6 Hz, 2H), 7.93 (d, J = 7.2 Hz, 2H), 10.40 (br, 1H). HRMS (ESI) [M + 
H]+ calcd for C15H13N2S, 253.0799; found 253.0802. 
 
N,4-Diphenylthiazol-2-amine (8b) (820 mg, 93%, white solid) was prepared from 
18 and according to the method described for 1b. 1H (DMSO-d6): 6.81 (d, J = 8.4 Hz, 
2H), 6.96 (t, J = 6.6 Hz, 1H), 7.06 (s, 1H), 7.33 (d, J = 8.4 Hz, 1H), 7.35 (d, J = 7.6 Hz, 
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1H), 7.71 (d, J = 7.6 Hz, 2H), 7.73 (d, J = 8.4 Hz, 2H), 10.22 (br, 1H). HRMS (ESI) [M + 
H]+ calcd for C15H13N2OS, 269.0749; found 269.0748. 
 
4-(2-(Phenylamino)thiazol-4-yl)benzene-1,3-diol (8c) (887 mg, 95%, light brown 
solid) was prepared from 18, and according to the method described for 1c. 1H (DMSO-
d6): 6.31 (d, J = 2.4 Hz, 1H), 6.33 (s, 1H), 7.02 (t, J = 7.2 Hz, 1H), 7.14 (s, 1H), 7.37 (t, J 
= 7.8 Hz, 2H), 7.53 (d, J = 7.2 Hz, 2H), 7.66 (d, J = 8.8 Hz, 1H), 10.43 (br, 1H). HRMS 
(ESI) [M + H]+ calcd for C15H13N2O2S, 285.0698; found 285.0701. 
 
2-(2-(Phenylamino)thiazol-4-yl)phenol (8d) (837 mg, 95%, white solid) was 
prepared from 18, and according to the method described for 1b except using 2-Bromo-
2’-hydroxyacetophenone 28. 1H (DMSO-d6): 6.87-6.92 (overlapped, m, 2H), 7.01 (t, J = 
7.4 Hz, 1H), 7.16 (t, J = 8.4 Hz, 1H), 7.37 (t, J = 7.4 Hz, 2H), 7.43 (s, 1H), 7.57 (d, J = 
7.6 Hz, 2H), 7.91 (d, J = 7.6 Hz, 1H), 10.40 (br, 1H). HRMS (ESI) [M + H]+ calcd for 
C15H13N2OS, 269.0749; found 269.0751. 
 
4-(4-Nitrophenyl)-N-phenylthiazol-2-amine (8e) (908 mg, 93%, orange solid) 
was prepared from 18, and according to the method described for 1b except using 2-
bromo-4’-nitroacetophenone. 1H (DMSO-d6): 7.00 (t, J = 7.4 Hz, 1H), 7.37 (t, J = 8.0 Hz, 
2H), 7.741 (d, J = 7.2 Hz, 2H), 7.744 (s, 1H), 8.19 (d, J = 9.2 Hz, 2H), 8.31 (d, J = 9.2 
Hz, 2H), 10.42 (bs, 1H). HRMS (ESI) [M + H]+ calcd for C15H12N3O2S, 298.0650; found 
298.0659. 
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Phenylthiazol-2-amine (10a) (444 mg, 96%, white solid) was prepared from 
thiourea 19 and according to the method described for 1a.  1H (DMSO-d6): 6.88 (d, J = 
8.8 Hz, 2H), 7.01 (s, 1H), 7.56 (d, J = 8.8 Hz, 2H), 8.90 (br, 2H), 9.95 (br, 1H). HRMS 
(ESI) [M + H]+ calcd for C9H9N2S, 177.0486; found 177.0481.  
 
4-(2-Aminothiazol-5-yl)phenol (10b) (480 mg, 95%, white solid) was prepared 
from 19 and according to the method described for 1b. 1H (DMSO-d6): 7.25 (s, 1H), 
7.44-7.52 (overlapped, m, 4H), 7.74 (d, J = 8.0 Hz, 2H), 8.80 (br, 2H).  HRMS (ESI) [M 
+ H]+ calcd for C9H9N2OS, 193.0436; found 193.0429. 
 
4-(2-Aminothiazol-5-yl)benzene-1,3-diol (10c) (520 mg, 95%, yellow solid) was 
prepared from 19 and according to the method described for 1c. 1H (DMSO-d6): 6.34 (dd, 
J = 8.4, 2.0 Hz, 1H), 6.44 (d, J = 2.0 Hz, 1H), 6.94 (s, 1H), 7.36 (d, J = 8.8 Hz, 1H), 8.79 
(br, 1H), 9.80 (br, 1H).  HRMS (ESI) [M + H]+ calcd for C9H9N2O2S, 209.0385; found 
209.0395. 
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5.1 Abstract 
 
More than 128 natural products, for which structures are known, show some type 
of anti-diabetic activity.  Visual inspection of these structures suggested that a subset may 
function by inhibition of fructose 1,6-bisphosphatase (FBPase), an enzyme critical in the 
control of gluconeogenesis. Using in silico docking methodology, the natural products 
that showed anti-diabetic activity were evaluated to determine those that exhibited 
affinity for the allosteric binding site of FBPase, where the natural inhibitor AMP binds. 
Based upon these in silico experiments, achyrofuran, a natural product derived from the 
South American plant Achyrocline satureoides, was selected for further investigation.  
Achyrofuran has been shown to significantly lower blood-glucose levels in mouse 
models for type-2 diabetes.  Since a genuine sample of achyrofuran was not available, we 
synthesized a series of achyrofuran analogs.  Compounds 15 and 16 were found to inhibit 
both human liver and pig kidney FBPases at IC50 values comparable to that of AMP, the 
natural allosteric inhibitor, providing strong evidence that FBPase is the in vivo target for 
the natural product. The identification of the natural target of achyrofuran is critical in the 
design of new anti-diabetic drugs based upon this compound. 
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5.2 Introduction 
 
Significant effort has been brought to bear towards the development of new 
therapeutics for the treatment of type-2 diabetes, specifically through the use of small 
molecule compounds binding to an enzyme target. A number of these have targeted 
fructose-1,6-bisphosphatase (FBPase, EC 3.1.3.11), an enzyme critically involved in the 
control of gluconeogenesis.1,2 In type-2 diabetes, the enzymatic control of 
gluconeogenesis is compromised, thus allowing the production of excessive amounts of 
glucose resulting in elevated blood glucose levels characteristic of the disease.  In normal 
individuals, when blood glucose levels are high there is a corresponding increase in the 
concentration of fructose 2, 6-bisphosphate, a potent competitive inhibitor of FBPase.3 
The increase in cellular concentrations of fructose 2, 6-bisphosphate is hormonally 
regulated by elevated insulin concentration.  However, the biology of type-2 diabetes 
patients is insulin resistance. 
 
FBPase is an allosteric enzyme composed of four identical chains (Mr 36,700) 
organized as a dimer of dimers. Regulation of enzymatic activity involves changes in 
quaternary structure between the active (R) and inactive (T) conformational states.4,5 
Metal cations, fructose 1, 6-bisphosphate, and fructose 6-phosphate stabilize the R state, 
while AMP binds to the allosteric site and inhibits the enzyme by shifting the enzyme 
from the R to the T conformation.  Fructose 2, 6-bisphosphate, a potent competitive 
inhibitor of FBPase, synergistically increases the binding affinity of AMP.1 As a drug 
   150 
target leading to inhibition of FBPase, there are three possible sites for small molecule 
binding: (i) the active site, which binds the substrate fructose 1, 6-bisphosphate (FBP) 
and the natural inhibitor fructose 2, 6-bisphosphate, (ii) the allosteric site, which binds 
AMP, and (iii) a ‘novel’ allosteric site6 located at the interface between the four 
monomers. 
 
Considerable research has been focused on designing small-molecule inhibitors of 
FBPase, since patients with hereditary fructose 1,6-bisphosphatase deficiency seem to 
develop normally after early childhood.7 Wright et al.8 reported a series of 
anilinoquinazolines as allosteric inhibitors of FBPase, identified by screening a library of 
compounds. However, they found that these anilinoquinazolines bound to the ‘novel’ 
allosteric site.  Another class of inhibitors identified by a high-throughput screen (HTS), 
which also bind to the ‘novel’ allosteric site, is a group of benzoxazole-2-benzene-
sulfonamides.9 Other small-molecule inhibitors, which bind to the allosteric site of 
FBPase and are competitive with the binding of AMP, include MB0503210 and 3-(2-
carboxy-ethyl)-4,6-dichloro-1H-indole-2-carboxylic acid.11  
 
The popularity of HTS as an approach to drug discovery is no doubt due to the 
ability to test a large number of potential effectors of biological activity against a 
biological event or an enzyme target such as FBPase.  As an alternative to HTS to 
identify novel FBPase inhibitors and/or new scaffolds, we decided to embark on a road 
less travelled but nonetheless relevant by focusing our attention on natural products that 
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have been identified to have anti-diabetic activity.  The use of natural products to treat 
diabetes is not a new concept.  Long before the advent of insulin, symptoms manifested 
from what we now know as diabetes were treated with plant medicines.  In fact, natural 
products from more than 1,200 species have been reported as being used for the treatment 
of diabetes.12 And hence, we speculate that there is a high probability that some of these 
natural products may function via the inhibition of FBPase. 
 
Zareba et al.12 summarized 128 natural products of known structure with anti-
diabetic activity.  Here, we evaluated the interactions of these natural products to the 
allosteric site of human FBPase using in silico docking methods. We selected 
achyrofuran (2, Figure 5.1) for further studies because of a number of reasons: (i) the in 
silico docking indicated that achyrofuran bound to the AMP site of FBPase with high 
affinity, (ii) achyrofuran is used as an anti-diabetic natural product,13 (iii) achyrofuran has 
proven potency as an anti-diabetic agent in mouse models,14 and (iv) achyrofuran has 
‘drug-like’ properties according to the Lipinski’s rule of 5.15 Using a combination of 
chemical synthesis and in vitro enzymatic activity measurements, there is sufficient 
evidence to support the proposal that the anti-diabetic activity of achyrofuran is due to its 
binding to the allosteric regulatory site of FBPase. 
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Figure 5.1. Structures of FBPase inhibitors. AMP (1), Achyrofuran (2), (+)-Usnic acid 
(3), Inhibitors (4),11 (5), (6),16 (7),17 (8),18 (9)9 and (10)10 are known inhibitors of FBPase 
that were docked against the enzyme using GLIDE.19 
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5.3 Results and Discussion   
 
In Silico Docking 
Zareba et al.12 divided 128 natural products, with known structures and anti-
diabetic activity, into 16 structural groups.  To evaluate the interactions of these natural 
products to the allosteric site of human FBPase by in silico docking methods, we used the 
GLIDE program.19,20 GLIDE was chosen as the main docking software because it proved 
to be more accurate than SURFLEX and twice as accurate as GOLD when the docking 
accuracy for GLIDE was assessed by redocking ligands from 282 cocrystallized PDB 
complexes.19  
 
We validated GLIDE for use with FBPase by three separate methods.  First, we 
docked AMP into the structure of the human enzyme with AMP bound (PDB entry 
1FTA).21 The receptor was setup by removing the AMP molecule from its site, and AMP 
was setup initially so that it was in a different spatial position, distant from the actual 
binding site.  AMP was then docked into the allosteric site using the high-precision mode 
(XP) of GLIDE.  GLIDE performed well in matching the docked conformation to the one 
observed in the crystal structure.  The root mean square (RMS) deviation between the 
position of AMP in the crystal structure and that obtained by GLIDE docking was 0.38 
Å. 
The second method used to validate the use of GLIDE with FBPase was to dock 
compound 4 into the pig kidney FBPase structure (PDB entry 1LEV). This structure has 
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4 bound in the allosteric site of the enzyme.11 Compound 4 was one of a set of indole 
carboxylic acid compounds identified via a HTS against human FBPase.11 Wright et al.11 
reasoned that the reported structure was a good model for the complex with the human 
enzyme, since the degree of amino acid sequence conservation within mammalian 
FBPases is very high (>95% identical or similar). 
 
 The RMS deviation between the position of 4 in the X-ray structure of the pig 
kidney FBPase (PDB entry 1LEV) and that determined by docking using the high-
precision mode (XP) of GLIDE to that structure was 1.07 Å.  This value of the RMS 
deviation indicated that the position obtained by docking was very similar to that 
observed in the X-ray structure.  When 4 was docked into the allosteric site of human 
FBPase (PDB entry 1FTA) the conformation and interactions observed in the human 
enzyme were again similar to those observed in the structure of the pig kidney enzyme 
and overlapped the position of AMP (see Figure 5.2). 
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Figure 5.2. Comparison of the docked position of 4 with AMP in the crystal structure. 
Compound 4 (sticks) was docked into the allosteric site of human FBPase (PDB code 
1FTA) and the best-docked conformation was overlapped with AMP (CPK).  The docked 
conformation of 4 overlaps the position occupied by AMP.21 This figure was created 
using PyMol.22 
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The third method used to validate GLIDE was to determine the relative binding 
affinities of a series of known FBPase that bind to the allosteric site (Figure 5.1). The 
calculations were performed using the high-precision mode (XP) of GLIDE.23 The 
resulting trend in the GLIDE XP docking score, as defined by Halgren et al.,23 correlated 
(correlation coefficient r = 0.9) well to the log of the published IC50 values (see Figure 
5.3). 
 
Figure 5.3. Correlation between experimentally observed IC50 values for FBPase 
inhibitors and the GLIDE XP Score. AMP (1) and known inhibitors of FBPase were 
docked into the allosteric site of human FBPase (PDB entry 1FTA) and the GLIDE high-
precision XP score calculated. The numbers associated with the data points in this figure 
correspond to the compounds in Figure 5.1. A more negative docking score represents 
tighter binding, and therefore should predict better inhibition. 
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Of the identified chemical compounds, known to be active anti-diabetic 
constituents from plants,13 seventy-one were docked into the allosteric site of the human 
FBPase structure, and the best-docked conformation of each was evaluated. Of the 
compounds docked, compound 2 was of particular interest, because when diabetic db/db 
mice were dosed orally with pure 2 at 20 mg/kg once per day, 2 was able to lower the 
serum glucose levels of these mice below those in the positive control group treated with 
Metformin, dosed at 250 mg/kg once per day.14 Compound 2 was originally isolated from 
Achyrocline satureioides, using a bioassay-guided fractionation using a diabetic db/db 
mouse model.14 A. satureoides, a medium-sized aromatic herb that grows throughout 
Brazil, Uruguay and Argentina, has been used in herbal medicine throughout this region 
to treat a variety of ailments including type-2 diabetes.  In addition, 2 also has ‘drug-like’ 
properties according to the Lipinski’s rule of 515 and bound, in silico, to the AMP site of 
human FBPase with an affinity that is comparable to that of AMP. 
 
Our docking results indicate that 2 makes a total of 14 contacts within the AMP 
binding site of FBPase, five hydrogen-bonding interactions and nine hydrophobic 
interactions. Compound 2 forms hydrogen bonding interactions with Thr27, Gly28, 
Glu29, Lys112 and Tyr113 and hydrophobic interactions with Gly21, Arg22, Gly26, 
Thr31, Arg140, Val 160, Met177, Asp178 and Cys179 (Figure 5.4).  In addition, 2 fills 
the space within the allosteric binding pocket better than AMP (Figure 5.5). 
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Figure 5.4. Interactions of achyrofuran with FBPase. (Top) 2 bound in the allosteric site 
of FBPase (PDB code 1FTA).  The protein-ligand interactions were determined using 
Ligplot.24 (Bottom) Schematic representation of 2 bound in the allosteric site of FBPase 
in the same orientation as shown in the top part of the figure. 
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Figure 5.5. Comparison of AMP and achyrofuran bound to FBPase. (a) AMP bound in 
the allosteric site of human FBPase as determined by X-ray crystallography (PDB entry 
1FTA, chain A). (b) Achyrofuran (2) docked in the allosteric site of human FBPase using 
the high-precision XP mode of Glide (Schrödinger). This figure was produced using 
PyMol.22 
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In order to support the hypothesis that 2 is an inhibitor of FBPase, we performed a 
substructure search to find a purchasable compound, as similar as possible to 2, to test in 
vitro.  From this search (+)-usnic acid (3), a naturally occurring dibenzofuran derivative 
found in several epiphytic lichen species was identified.  The high-precision mode (XP) 
of GLIDE23 was used to dock 3 into the allosteric site of FBPase. The results from 
GLIDE indicated that 3 had reasonable affinity for the allosteric site, although 
significantly less than 2. Activity measurements showed that 3 was able to inhibit FBPase 
in vitro. As seen in Table 1, compound 3 inhibited both human liver and pig kidney 
FBPases with IC50 values of 0.37 and 0.93 mM, respectively. 
 
Design, Synthesis and Characterization of Novel Achyrofuran Analogs 
Since an authentic sample of achyrofuran was not available, it was impossible to 
determine if achyrofuran inhibits FBPase in vitro.  In order to provide additional evidence 
that achyrofuran was an allosteric inhibitor of FBPase, we synthesized analogues bearing 
the achyrofuran core structure.  The rationale being that if these analogues inhibited both 
human liver and pig kidney FBPases, then it would provide further support for our 
hypothesis.  Based upon the modeling of about twenty analogues, we selected 15 and 16 
as our first synthetic targets because they (i) docked with similar affinity to FBPase as 2, 
and (ii) could be readily synthesized using modifications of published procedures. Since 
stereochemistry at the three stereogenic centers of achyrofuran was never determined, 15 
was designed to possess no chiral centers, while 16 was synthesized as a mixture of 
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stereoisomers.  We also reasoned that in removing the methypentenol and methylpentene 
groups, the hydrophilicity should be increased. 
 
The synthesis of compounds 15 and 16 is illustrated in Figure 5.6.  The synthesis 
of 12 was accomplished by the single iodination of commercially available 1,3,5-
trimethoxybenzene (11) using solid iodine in the presence of iodic acid, as previously 
described with modifications.25 Since 1,3,5-trimethoxybenzene is a symmetrical 
molecule, the reaction was allowed to proceed freely without the need to control the 
position for substitution. Next, the biphenyl intermediate 13 was synthesized by an 
Ullmann coupling.  Conventionally, the Ullmann reaction is carried out in the presence of 
copper bronze.25,26 However, we found that by substituting solid copper for the copper 
bronze the yields were substantially improved. Cyclization and the concomitant 
deprotection of 13 in a 1:1 mixture of HBr and acetic acid25 conveniently yielded 14 as 
the key intermediate. Next, we were faced with the challenge of functionalizing 14 with 
the appropriate acyl moiety.  Attempts to introduce the isovaleryl group on the ring with 
isovaleryl chloride and tin (IV) chloride,27 as well as with isovaleric acid and boron 
trifluoride,26 proved unsuccessful.  We reasoned that the isovaleryl portions could be 
strategically placed by means of a Friedel Crafts reaction to ultimately yield 15. 1H 
chemical shifts of the two dibenzofuran protons at δ 6.77 and 7.27, respectively, proved 
that the Friedel Crafts acylation with AlCl3 had successfully placed the isovaleryl 
functionalities on opposing sides of the ring. Having successfully synthesized 15, the 
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same strategy was applied in synthesizing 16 by simply substituting isovaleryl chloride 
with 2-methylbutyryl chloride. 
 
 
 
Figure 5.6. Synthetic scheme for inhibitors 15 and 16: (a) I2, HIO3, EtOH, reflux, 18 h 
(b) Cu(s), 235 °C, 1 h (c) HBr, AcOH, reflux, 18 h (d) acid chloride, AlCl3, CS2, CHCl3, 
50 °C, 1 h. 
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Compounds 15 and 16 were tested to determine if they could inhibit either pig 
kidney and human liver FBPase using a coupled-enzyme assay28 using the natural 
allosteric inhibitor AMP as a control. Compound 15 was found to inhibit pig kidney 
FBPase with an IC50 of 1.5 µM as compared to 1.3 µM for AMP, while the same 
compound inhibited human liver FBPase with an IC50 of 8.1 µM as compared to 9.7 µM 
for AMP. Compound 16, containing the 2-methylbutyryl functionality, inhibited the pig 
and human FBPases with IC50 values of 5.0 and 6.0 µM, respectively. (+)-Usnic acid 
inhibited the enzyme with IC50 values of 930 and 371 µM while the dibenzofuran 
scaffold 14 did not inhibit either enzyme. The ability of (+)-usnic acid to inhibit the 
enzymes, might be due to the presence of the carbonyl moieties at C1 and C1’.  The 
carbonyl functionalities are an integral part of achyrofuran and are also present in 15 and 
16 while being absent in 14.    
 
Table 5.1. IC50 Values of Human Liver and Pig Kidney FBPase Intermediates and 
Inhibitors. 
Compound Pig kidney FBPase 
IC50 (µM) 
Human liver FBPase 
IC50 (µM)] 
AMP 1.3 ± 0.1 9.8 ± 0.1 
Usnic Acid 930 ± 11 371 ± 13 
15 1.5 ± 0.1 8.1 ± 0.8 
16 5.0 ± 0.3 6.0 ± 0.3 
14 ND[a] ND[a] 
[a] No inhibition observed. 
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In order to confirm that the FBPase inhibition by the achyrofuran analogs was due 
to binding at the allosteric site and not the active site, a competition experiment was 
performed using the AMP analogue, 2’,3’-O-(2,4,6-trinitrophenyl)adenosine 5-
monophosphate (TNP-AMP).  This analogue has been shown to bind at the allosteric site 
of FBPase and exhibits fluorescence only when bound to the enzyme.29 In separate 
experiments, TNP-AMP was added to pig kidney and human liver FBPase at a 
concentration equal to 0.5 times their respective IC50 values for AMP. Subsequently, 
increasing concentrations of 15 or 16 were added to the above solution, which resulted in 
a substantial diminution of the TNP-AMP fluorescence, indicating that both 15 and 16 
were competing with TNP-AMP at the allosteric site. Binding constants for 15 and 16 
could not be determined by this method due to the relatively low solubility of these 
compounds. 
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5.4 Conclusion 
 
Natural products and their derivatives have historically been invaluable as a 
source of therapeutic agents. Of the 877 small-molecule New Chemical Entities (NCEs) 
introduced between 1981 and 2002, approximately 49% were either natural products, 
semi-synthetic natural-product analogs or synthetic compounds based on natural-product 
pharmacophores.30 This, together with the notion that natural-product structures have 
long been recognized to possess characteristics of high chemical diversity, biochemical 
specificity and molecular diversity within the boundaries of reasonable drug-like 
properties, make them attractive targets as lead structures for drug discovery.31 One 
drawback to the optimization of natural products into viable drugs is, at least in many 
cases, the lack of the identity of the in vivo target of the compound. Here we employed in 
silico docking methods to determine which of the known anti-diabetic natural products 
can potentially inhibit FBPase. In addition, the present work demonstrates the ability of 
achyrofuran analogs 15 and 16 to inhibit both pig kidney and human liver FBPase with 
comparable IC50 values to those of the natural allosteric inhibitor AMP. Furthermore, the 
data suggest that 15 and 16 compete with AMP for its binding site, indicating the 15 and 
16 are new allosteric inhibitors of these enzymes.  Based upon these results, we propose 
that FBPase may be the in vivo target for the anti-diabetic component in Achyrocline 
satureioide, achyrofuran (2). Knowledge of the in vivo target of achyrofuran will allow 
the design of more potent achyrofuran based anti-diabetic agents. In addition, the fact that 
15 and 16 have similar structures to achyrofuran and follow Lipinski’s rule of five15 
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suggest that these compounds or their derivatives have the potential to be developed into 
a new class of anti-diabetic drugs.  Although we only concentrated on achyrofuran in this 
work, many of the other anti-diabetic compounds docked as potential allosteric FBPase 
inhibitors can be pursued as new drug scaffolds in the future based upon our findings. 
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5.5 Experimental 
 
Molecular modeling 
Docking of AMP and inhibitors to human liver and pig kidney FBPase was 
performed using Glide (Schrödinger, Inc.)19,20 in the high-precision (XP) mode. The 
necessary grids were prepared based on structures in the Protein Data Bank (PDB), 
namely 1FTA21 and 1EYK32 for the human and pig enzymes, respectively. The 
coordinates of AMP in the respective structures were used as the center of the grid box. 
3D structures of AMP and inhibitors were generated using Maestro (Schrödinger, Inc.), 
and then processed through LigPrep (Schrödinger, Inc.), to produce a number of versions 
of the inhibitor structures with various ionization states, tautomers and stereochemistries 
as necessary for each case. 
 
Isolation and purification of human liver FBPase 
An expression plasmid (pEK694) for human liver FPBase was constructed by inserting 
the human liver FBPase gene from plasmid EX-C0133-B31 (GeneCopoeia) into the 
vector pET23a (Novagen, Inc.).  The FBPase gene from EX-C0133-B31 had a C-terminal 
6xHis tag for use in purification.  
 
For expression of the human liver FBPase, chemically competent BL21(DE3) 
Rosetta cells (Novagen, Inc.) were transformed with pEK694.  A 5 mL overnight culture 
grown in LB media33 with 150 µg/mL of ampicillin was back-diluted 1000-fold into 2 L 
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of 2YT33 media with 0.4% glycerol and 150 µg/mL ampicillin.  Bacterial growth at 37°C 
was monitored at 560 nm and the doubling-time was calculated.  When the growth 
reached an O.D. 0.4 at 560 nm, 0.1 mM IPTG was added to induce the cell, following 
which the cells were allowed to grow for three additional doubling times.  The cells were 
then harvested by centrifugation (4400 x g), resuspended in 5 mM K2HPO4, pH 7.4, 2.5 
µg/mL leupeptin, 0.1 mg/mL lysozyme and 50 mM imidazole and lysed by sonication. 
The lysate was clarified by centrifugation at 31,000 x g for 15 min. The protein was 
purified through a Chelating Sepharose Fast Flow column (GE Healthcare), which had 
been charged with 0.3 M NiSO4. Proteins that did not bind to the column were eluded 
with 10 column volumes of 50 mM imidazole, pH 7.5.  The human liver FBPase was 
then eluted with buffer containing 50 mM sodium citrate and 50 mM NaCl, pH 4.0.  The 
standard elution procedure using high concentrations of imidazole could not be 
employed, since the enzyme precipitated under these conditions.  The protein-containing 
fractions were pooled and dialyzed against 50 mM Tris-acetate buffer, 150 mM NaCl, pH 
7.5 at 4 °C overnight. Protein purity was confirmed by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis.34 Protein concentration was determined using the 
BioRad version of the Bradford dye-binding assay35 with bovine serum albumin as the 
standard.  
 
Isolation and purification of pig kidney FBPase 
In order to purify the pig kidney FBPase more efficiently, by metal chelating 
chromatography, six His residues were added to the C-terminal of the enzyme.  This was 
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accomplished by mutating the last two codons of the pig kidney FBPase sequence in 
plasmid pEK28436 to a XhoI site, by site-specific mutagenesis. The new plasmid was 
then digested with XhoI and the resulting fragments separated on an agarose gel. The 
larger fragment (4.6 Kb) was purified from the agarose gel and then religated by adding 
T4 DNA ligase at 12° C for 12 hrs.  The new plasmid pEK324 had the pig kidney coding 
sequence with the last two codons replaced with the codons for Leu-Glu-His-His-His-
His-His-His.  Competent E. coli BL21(DE3) cells (Novagen, Inc.) were transformed with 
pEK324 and grown in YT33 media at 37 °C, containing 150 µg/mL ampicillin.  Bacterial 
growth at 37°C was monitored at 560 nm and the doubling-time was calculated. When 
the growth reached an OD at 560 nm of 0.7, cells were induced with 0.4 mM IPTG and 
allowed to grow for an additional 18 h. The cells were harvested and purified according 
to the method described above for the human liver FBPase. 
 
Measurement of FBPase activity 
FBPase activity was measured spectrophotometrically by employing the coupling 
enzymes phosphoglucose isomerase and glucose-6-phosphate dehydrogenase.28 The 
reduction of NADP+ to NADPH was monitored directly at 340 nm. Specifically, buffer 
(0.2 M Tris, 4 mM MgCl2, 4 mM (NH4)2SO4, 0.1 EDTA, pH 7.5), 0.2 mM of NADP+, 
1.4 units of phosphoglucose isomerase and 0.5 units of glucose-6-phosphate 
dehydrogenase, 0 – 300 µM of inhibitor and 9 ng of FBPase, were mixed in a cuvette and 
equilibrated at 30° C.  70 µM of FBP was then added to initiate the reaction.  A340 data 
were collected as a function of time, using a JASCO V-630 spectrophotometer.  After a 
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lag phase due to coupling, a straight line was fitted to the progress curve and the slope 
value was recorded as ΔA340 per min. The amount of NADPH produced per minute was 
calculated using the 340 nm millimolar extinction coefficient of 6.22. At each inhibitor 
concentration, reactions were performed in duplicate. Inhibition curves were obtained for 
each compound by plotting the relative activity versus inhibitor concentration. 
 
Fluorescence measurements 
Fluorescence data were collected using a JASCO FP-6300 spectrofluorometer. 
Excitation and emission wavelengths of 410 and 535 nm respectively were used for TNP-
AMP (Molecular Probes).  0.15 mg of the respective FBPases, 0.08 mM MgCl2 and 20 
µM fructose 1,6-bisphosphate in 50 mM Tris-acetate buffer, pH 7.5, was added to a 2 mL 
cuvette and stirred. 3.5 µM of TNP-AMP was added to the cuvette and the fluorescence 
emission was measured.  Microliter volumes of 15 were added sequencially with the 
fluorescence emission recorded after each addition. The final concentration of 15 in the 
enzyme solution was 6 µM. The competition experiment for 16 was performed in the 
same manner as described for 15. 
 
Chemistry 
All materials were reagent grade and used without further purification. Thin-layer 
chromatography (TLC) was performed on silica gel 60 aluminum backed pates (250 
microns) from Sorbent Technologies and visualized by A254 irradiation. Flash 
chromatography was conducted with silica gel 60 (230 mesh) from AK Scientific Inc. 1H 
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NMR spectra were recorded on a Varian 400 spectrometer.  Proton chemical shifts are 
reported in ppm (δ) relative to internal tetramethylsilane (TMS, δ 0.0) or with the solvent 
reference relative to TMS employed as the internal standard (CDCl3, δ 7.24 ppm; DMSO-
d6, δ 2.50). Standard abbreviations indicating multiplicity were used as follows: s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet and br = broad.  Mass spectra 
were obtained at the Mass Spectrometry Facilities at Boston College. HPLC separations 
were performed on a Biologic Duo Flow chromatography system (BioRad). 
 
2-Iodo-1,3,5-trimethoxybenzene (12) 
1,3,5-Trimethoxybenzene (14.5 g, 0.086 mol) was dissolved in 10 mL of ethanol 
at rt before warming to 50° C in a waterbath after which, an aqueous solution of iodic 
acid (7.6 g, 0.043 mol) was added. Solid iodine (21.88 g, 0.086 mol) was dissolved in 20 
mL of ethanol and the resultant solution was added portion-wise over 60 min to the 
reaction mixture. Stirring was continued at 50° C until the color of I2 faded and a white 
precipitate appeared. The reaction mixture was stirred at rt for 18 h. The precipitate that 
formed was isolated via vacuum filtration, washed with ethanol and crystallized from 
methanol to yield 12 (21.7 g, 86%) as white crystals. m.p. 120 – 122° C (Lit. 119 – 121° 
C25); 1H NMR (400 MHz, DMSO-d6): δ 3.80 (s, 9H, overlapped, 2 x ICCOCH3  and 
CHCOCH3), 6.28 (s, 2H, CCHC);  13C NMR (DMSO-d6, 100 MHz) 54.9, 55.5, 91.1, 
116.5, 158.6, 160.0; ESI-HRMS [M + H]+: calc. for C9H12IO3: 294.9831, found: 
294.9842. 
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2,2',4,4',6,6'-Hexamethoxybiphenyl (13) 
Compound 12 (7.0 g, 0.024 mol) and copper powder (2.0 g, 0.031 mol) were 
mixed thoroughly and transferred to a heavy wall, pressure vessel.  The vessel was placed 
into a sand-bath at the initial temperature of 120° C.  Once the vessel was secured, the 
temperature of the bath was raised to 235° C in 15 min and kept at 235° C for 1 h.  The 
vessel was allowed to cool and the contents removed and powdered.  The product was 
extracted with methanol for 18 h in a soxhlet.  The resultant solution was concentrated in 
vacuo.  Purification of the crude reaction mixture via column chromatography (1:5 ethyl 
acetate/hexane) yielded 13 (3.1 g, 78%) as a white solid:  m.p:  155 – 157° C (Lit. 156° 
C25); 1H NMR (400 MHz, DMSO-d6): δ 3.58 (s, 12H, 4 x CCOCH3), 3.78 (s, 6H, 2 x 
CHCOCH3), 6.21 (s, 4H, 4 x CHCOCH3); 13C NMR (DMSO-d6, 100 MHz) 55.1, 55.4, 
90.5, 92.8, 158.7, 161.1; ESI-HRMS [M + H]+: calc. for C18H23O6: 335.1495, found: 
335.1502. 
 
1,3,7,9-Tetrahydroxydibenzofuran (14) 
Compound 13 (3 g, 8.97 mmol) was refluxed for 18 h in a 20 mL solution 
consisting of a 1:1 mixture of HBr and acetic acid.  The reaction mixture was neutralized 
by adding saturated aqueous NaHCO3. The subsequent mixture was then extracted with 
ethyl acetate and the organic layer was further washed with brine, water and dried over 
Na2SO4. After removing the solvent in vacuo, the brown, viscous residue was purified by 
column chromatography (5-20 % ethyl acetate/hexane) to yield 14 (1.6 g, 77%) as a 
yellow solid: m.p: 94 – 96° C; 1H NMR (400 MHz, DMSO-d6): δ 6.23 (s, 2H, 
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OHCCHCOH), 6.45 (s, 2H, OCCHCOH), 9.59 (s, 2H, 2 x OHCCHCOH), 10.18 (s, 2H, 2 
x OCCHCOH); 13C NMR (DMSO-d6, 100 MHz) 90.5, 97.3, 115.1, 149.1, 156.6, 157.2; 
ESI-HRMS [M + H]+: calc. for C12H9O5: 233.0450, found: 233.0459. 
 
1,1'-(1,3,7,9-tetrahydroxydibenzofuran-2,6-diyl)bis(3-methylbutan-1-one) (15) 
Compound 14 (100 mg, 0.431 mmol) and aluminum trichloride (287 mg, 2.15 
mmol) were suspended in 5 mL of carbon disulfide at rt. Chloroform (6 mL) was added 
to the suspension and the reaction mixture was warmed to 50° C in a water-bath. 
Isovaleryl chloride (259 mg, 2.15 mmol) was added dropwise and the reaction was stirred 
for 2 h at 50° C.  After removing solvent in vacuo, and the crude reaction mixture was 
purified by column chromatography (1-5% ethyl acetate/hexane) to yield 15 (30 mg, 
17%) as a white solid: 1H NMR (400 MHz, CDCl3): δ 1.04 -1.07 (m, 12H, 4 x 
CH2CHCH3), 2.23 – 2.26 (m, 2H, CH2CHCH3), 2.44 (d, J = 7.2 Hz, 2H, OHCCCCH2), 
2.54 (d, J = 6.8 Hz, 2H, OCCCCH2CHCH3), 6.77 (s, 1H, CCHC), 7.27 (s, 1H, OCCHC); 
13C NMR (CDCl3, 100 MHz) 23.0, 24.1, 26.4, 51.1, 54.2, 87.7, 101.1, 108.9, 113.2, 
117.2, 117.3, 152.3, 155.8, 156.5, 157.8, 160.4, 163.7, 200.1, 205.8; ESI-HRMS [M + 
H]+: calc. for C22H25O7: 401.1600, found: 401.1614. 
 
1,1'-(1,3,7,9-tetrahydroxydibenzofuran-2,6-diyl)bis(2-methylbutan-1-one) (16)  
Compound 16 was synthesized according to the same procedure as described for 
15, by substituting isovaleryl chloride with 2-methylbutyryl chloride (3.36 mmol, 429.0 
µL) to yield the desired product (40 mg, 15%) as white solid: 1H NMR (400 MHz, 
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CDCl3): δ 1.00 – 1.06 (m, 6H, CCCHCH3 and CCCHCH2CH3 overlapped), 1.29 (d, J = 
6.8 Hz, 3H, OCCCCHCH3), 1.33 (dd, J = 7.0, 4.2 Hz, 3H, OCCCCHCH2CH3), 1.60–1.66 
(m, 2H, CCCHCH2CH3), 1.80–1.87 (m, 2H, OCCCCHCH2CH3), 2.63 – 2.74 (m, 2H, 
CCCHCH3 and OCCCCHCH2CH3 overlapped) 6.74 (s, 1H, CCHC), 7.26 (s, 1H, 
OCCHC). 13C NMR (CDCl3, 100 MHz) 12.2, 15.3, 15.7, 25.0, 25.6, 43.8, 47.9, 95.5, 
100.1, 105.2, 113.3, 114.5, 115.1, 160.2, 152.6, 158.5, 161.4, 164.7, 202.3, 212.4. ESI-
HRMS [M+H]+: calc. for C22H25O7: 401.1600, found: 401.1611. 
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1) HPLC Conditions 
Purity Determinations by HPLC for key compounds:  
Method A 
Phenomenex C18 Gemini 3 micron column (100 x 2.00 mm), isocratic 
elution at 95 % acetonitrile in water at 1 mL/min. 
 
Method B 
Phenomenex C6-phenyl Gemini 5 micron column (100 x 4.60 mm), isocratic 
elution at 95 % acetonitrile in water at 0.2 mL/min. 
 
Table 1: The retention time of final compounds using Methods A and B. 
Method A Method B  
Cpd Purity 
(%) 
Retention Time 
(min) 
UV 
(nm) 
Purity 
(%) 
Retention Time 
(min) 
UV 
(nm) 
15 >99 10.27 254 >99 16.45 254 
16 >99 16.24 254 >99 22.17 254 
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HPLC traces: Compound 15 
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